

## Index of subjects Volume 5 (1994)

(Abstract Supplements 5 and 8 not included)

**A**

**ABVD**  
long-term results in advanced Hodgkin's disease S2: 53  
acquired immune deficiency syndrome (AIDS)  
aetiology of HIV-related lymphoma S2: 29  
and Hodgkin's disease S2: 37  
and related lymphoma 487, S2: 29, S2: 41  
Epstein-Barr gene expression in AIDS-related non-Hodgkin's lymphomas S1: 113  
MGBG: results in AIDS-related lymphomas 487  
prognostic factors in HIV-associated lymphomas 487, S2: 41  
**acromegaly**  
associated with malignancies 659  
**activation**  
of the X chromosome in non-Hodgkin's lymphomas S1: 47  
**adaptive dosing**  
and possible improvement of results S4: 9  
**ADEPT**  
antibody directed enzyme prodrug therapy in the treatment of cancer 879  
**adjuvant therapy**  
and cardiotoxicity in breast cancer 209  
chemo- and radiotherapy for biliary and pancreatic cancer S3: 73, S3: 81  
for breast cancer 717  
for colorectal cancer S3: 97  
for gastric cancer S3: 49  
second malignancies following 785, 803  
timing of baseline quality of life in breast cancer 65  
15 years follow-up of Ludwig I-IV trials 717  
**adverse effects**  
after long-term 5-FU, prednisone and  $\alpha$ -interferon 245  
following emetogenic chemotherapy and ondansetron 98  
with docetaxel 185  
with paclitaxel 474, 827  
**age**  
as prognostic factor in HD S2: 37  
in the treatment of lymphoma (Editorial) 873  
**alkylating agents**  
and minor-groove binding (Editorial) 877  
phase I study of the novel distamycin derivative tallimustine 901  
**ALL (see also leukemias)**  
and acute lysis syndrome 379  
heterogeneity in HIV-seropositive patients 437  
**all-trans-retinoic acid (see also retinoic acid)**  
and teratogenesis S9: 39  
as radiosensitizer S9: 3  
combined with  $\alpha$ -interferon in cell lines S9: 7  
combined with radiation in cell lines S9: 3, S9: 7  
for differentiation S9: 3, S9: 17  
for growth-inhibition S9: 7  
pharmacokinetic of S9: 33  
**allogeneic bone marrow transplantation**  
and bcl-2 quantification in low-grade lymphoma S1: 43  
for myelodysplastic syndrome and secondary leukaemias 401  
**alopecia**  
minoxidil as a prophylaxis 69  
**alpha-fetoprotein**  
in advanced hepatocellular carcinoma 646  
in endodermi sinus tumor and clear cell ovarian cancer 753  
**alpha-interferon (see interferons)**  
**amiodarone**  
to overcome MDR 659  
**anaplastic large cell lymphoma**  
a distinct clinicopathologic entity S1: 25  
and CD30 expression 300, 317  
and degree of anaplastic morphology 317  
in childhood S1: 31  
long term prognostic importance of primary ki-1 (CD30) antigen expression and anaplastic morphology in adult patients with diffuse large-cell lymphoma 317  
**angiogenesis**  
and gene therapy S4: 45  
and retinoids S9: 17  
clinical prognostic significance 305  
**angiosarcoma**  
of the residual breast 163  
**animal model**  
for hepatic artery occlusion 961  
growth of HD-cell lines in SCID-mice S1: 121  
xenografts and drug screening 396, 415  
**anosmia**  
associated with alpha-interferon treatment 863  
**anthracyclines**  
cardiotoxicity 98  
cardiotoxicity after adjuvant breast treatment 196, 209  
FAC and FEC in breast cancer 95  
indium-111 scintigraphy in diagnosis of cardiotoxicity by 617  
randomised trial of epirubicin vs. fluorouracil in advanced gastric cancer 33  
**anti-angiogenesis**  
and vascular targeting S4: 45  
in the future of anticancer treatment 305  
**anti-Tac monoclonal anti-body**  
and lymphokines S1: 13  
**antibiotics**  
duration of i.v. treatment for neutropenic fever 441  
**antibody-enzyme conjugates**  
in the treatment of cancer 879  
**anticancer drugs**  
adapting methodology of phase I trials S4: 67  
and angiogenesis 305  
and antisense S4: 55  
and immunotargeting 703

- and novel approaches in therapy 205
- and possible improvement through pharmacokinetics S4: 9
- antiemetic**
  - a phase I of MDL 73,147EF, chemotherapy 549
  - and vascular toxicity and thrombocytopenia 98
  - dose-finding study of tropisetron 821
  - new directions in research 569
  - ondansetron and dexamethasone 253
  - oral granisetron alone and in combination with dexamethasone 579
  - state-of-the-art 569
- antifolate**
  - edatrexate in advanced soft tissue sarcoma 766
  - edatrexate in hepatocellular carcinoma 646
  - edatrexate in pancreatic carcinoma 286
- antimetabolite**
  - edatrexate in hepatocellular carcinoma 646
  - edatrexate in pancreatic adenocarcinoma 286
  - edatrexate in soft tissue sarcoma 766
- antisense**
  - a new approach for anticancer drugs S4: 55
  - and regulation of chemoresistance by bcl-2 S1: 61
  - therapeutic use in lymphoma S1: 67
- apoptosis**
  - and expression of bcl-2 in breast cancer 409
  - and retinoids S9: 3, S9: 17
  - bcl-2 and solid tumours 388
  - non-Hodgkin's lymphoma and lymphocytic leukemia S1: 61
  - physiological basis 119
- aredia (see pamidronate)**
- aromatase inhibitors**
  - basic concepts S7: 3
  - formestane vs. tamoxifen in first-line treatment S7: 19
  - in the treatment of advanced postmenopausal breast cancer S7: 7
  - treatment of advanced breast cancer with formestane S7: 11, S7: 15
- aspergillosis**
  - chemoprophylaxis 571
- asthenia**
  - and CSFs 473
- AUC**
  - and teratogenesis of retinoids S9: 39
  - limited sampling models for topotecan pharmacokinetics 259
- autologous bone marrow transplantation**
  - and PBPC 781, 935
  - as consolidation therapy for follicular lymphoma S2: 143
  - comparison with peripheral blood stem-cell for lymphoma patients S95, S2: 151
  - consensus conference on 19
  - early in the course of Hodgkin's disease S2: 161
  - for low-grade non-Hodgkin's lymphoma: the EBMT experience S2: 147
  - in breast cancer 674
  - in first complete remission for high-grade non-Hodgkin's lymphoma S2: 155
  - role in Hodgkin's disease S2: 17
- axillary nodes**
  - current controversies in the surgical management of breast cancer S4: 39
- 5-aza-2'-deoxycytidine**
- and upregulation of epidermal growth factor receptor on human epithelial cancer cells 269**
- AZQ**
  - in human tumor xenografts 415
- B**
- bcl-1**
  - and mantle cell lymphoma 507
- bcl-2**
  - and apoptosis 119
  - and solid tumors 388
  - before and after allogeneic bone marrow transplantation S1: 43
  - biology of 199, S1: 61
  - expression in primary breast cancer 409
  - intensive conventional-dose chemotherapy for stage IV low-grade lymphoma and to negative of S2: 73
  - regulation of chemoresistance by S1: 61
- bcl-6**
  - in diffuse large-cell lymphoma S1: 55
- biliary cancer**
  - adjuvant radiotherapy and chemotherapy for biliary cancer S3: 75
  - edatrexate in the treatment of 286
- biochemotherapy**
  - with thymosin- $\alpha$ 1, IL-2 and dacarbazine in metastatic melanoma 741
- biological response modifiers**
  - annual review (book) 231
- biology**
  - of B- and T-cell lymphomas 689
  - of bcl-2 119, S1: 61
  - of Hodgkin's disease S1: 105
  - of primary mediastinal lymphoma 847, 943
- bisphosphonates**
  - and delayed progression of bone metastases S7: 41
  - and palliation of bone metastases S7: 37, S7: 45
  - effect on the mechanical properties of canine bone S7: 49
  - infusion rate and safety S7: 27
  - treatment of tumour-induced hypercalcaemia with pamidronate 359
- bladder cancer**
  - weekly gemcitabine in 182
- body composition**
  - and resting energy expenditure in the treatment of SCLC 915
- bone metastases**
  - and pamidronate S7: 31, S7: 37, S7: 41
- bone resorption (see also bisphosphonates)**
  - and pamidronate 359
- brain tumor**
  - concentration of paclitaxel in 951
  - incidence, and outcome of primary central nervous system lymphomas 349
- breast angiosarcoma**
  - after conservative surgery and radiotherapy for primary carcinoma 163
- breast cancer**
  - adjuvant chemohormonal treatment 717
  - adjuvant treatment and cardiotoxicity 209
  - and angiogenesis 305
  - and second malignancies 785, 803
  - application of molecular genetics to S4: 17
  - carboplatin and etoposide as first line treatment 858

dose-escalation with G-CSF 217  
 dose-escalation with GM-CSF 43, 709  
 elsamitrucin: a phase II trial 375  
 FAC after FEC 95  
 FLAC and GM-CSF in the treatment of 217  
 formestane in the treatment of S7: 1, S7: 7, S7: 11, S7: 15, S7: 19  
 goserelin with or without tamoxifen in 337  
 hormonal treatment for 337, 717, S7: 1  
 in males 83  
 molecular biology of S4: 31  
 m-VAC: a phase II study in 93  
 neoadjuvant chemotherapy and radiotherapy in stage IIb, IIIa 591  
 ovarian ablation vs. goserelin 337  
 palliation with pamidronate S7: 45  
 pamidronate in the treatment of S7: 31, S7: 37, S7: 41, S7: 45  
 preoperative treatment with taxol 863  
 prognostic significance of angiogenesis 305  
 prognostic significance of bcl-2 409  
 prognostic significance of cathepsin D 329  
 radiotherapy alone in stage IIb-IIIa 591  
 rationale of high-dose chemotherapy for 674  
 suramin: a phase II trial 597  
 surgical management of S4: 39  
 taxol in the treatment of 863, S6: 17, S6: 23  
 taxotere as second line treatment 527  
 timing of QL assessment 65  
 timing of surgery 25, 29  
 vinorelbine as first line treatment 854  
 vinorelbine as salvage treatment 423  
 breast irradiation  
 and late cardiotoxicity 209  
 bromodeoxyuridine  
 and cell kinetics of human ovarian cancer 627

**C**

CABO  
 vs. CF and cisplatin alone in head and neck tumors 521  
 camptothecins  
 doses, infusions and choice of schedule S4: 25  
 cancer  
 and angiogenesis 305  
 and palliative treatment (book) 195  
 chemotherapy for (book) 231  
 gene transfer in tumor therapy 789  
 quality-of-life assessment in palliative care 13  
 cancer care  
 patient participation in the cancer consultation 199  
 quality assessment of palliative care 13  
 cancer-related pain  
 oral tramadol and morphine for 141  
 the fight against it: state-of-the-art 111  
 candidiasis  
 chemoprophylaxis of fungal infections in neutropenic patients 571  
 carboplatin  
 carboplatin and paclitaxel in ovarian carcinoma S6: 39  
 intraperitoneally in ovarian carcinoma 127, 133  
 phase II study with etoposide in metastatic breast cancer 858  
 randomized comparison of etoposide-cisplatin vs. etoposide

carboplatin and irradiation in small-cell lung cancer 601  
 weekly carboplatin and VM-26 for elderly patients with small-cell lung cancer 369  
 cardiac toxicity  
 following adjuvant chemotherapy and breast irradiation 196, 209  
 high, with a 4-drug combination 641  
 of epirubicin 98  
 usefulness of indium-111 antimyosin scintigraphy in the diagnosis of 617  
 cathepsin D  
 prognostic value in breast cancer 329  
 CAV  
 as third-line salvage therapy for Hodgkin's disease 427  
 CCND1  
 cyclin D1 overexpression in non-Hodgkin's lymphoma with chromosome 11 bcl-1 rearrangement S1: 71  
 in mantle cell lymphoma 507  
 CD30  
 which is its nature? 300  
 CD34  
 positive cells and autografting 935  
 CD40  
 to evaluate peripheral blood progenitor cells 781, 795  
 CDRIII regions  
 in B-cell lymphoma S1: 79  
 cell cycle  
 and apoptosis 119  
 and bcl-1 507, S1: 71  
 and bcl-2 388  
 and retinoids S9: 11, S9: 17  
 mechanism of action of paclitaxel S6: 3  
 centrocytic lymphoma (see also mantle cell lymphoma)  
 cyclin D1 overexpression in S1: 71  
 mantle-cell lymphoma 507, S1: 35  
 cervical cancer  
 incidence, mortality and survival in Vaud, Switzerland, 1974-1991 747  
 chemoresistance  
 regulation by the bcl-2 oncogene in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines S1: 61  
 chemotherapy  
 a) combination  
 a four-drug combination in non-small-cell lung cancer 641  
 ABVD in Hodgkin's disease S2: 53  
 adjuvant chemo-hormonal treatment in breast cancer 717  
 CABO vs. cisplatin vs. CF in head and neck tumors 521  
 carboplatin and etoposide in first-line for breast cancer 858  
 CAV as third-line salvage in HD 427  
 CHOEP vs. hCHOP/iVEP in lymphoma 49  
 CHOP vs. chlorambucil in low-grade S2: 67  
 CHVmp-VB vs. proMACE-MOPP in lymphoma S2: 85  
 dacarbazine and 5-FU in medullary thyroid cancer 763  
 ECF in gastric cancer 609  
 ELF combination in gastric cancer 90  
 epirubicin, cisplatin and 5-FU in gastric cancer 609  
 E-SHAP in relapsed non-Hodgkin's lymphoma 453  
 FAC and FEC in breast cancer 95  
 5-FU and cisplatin in nasopharyngeal carcinoma 87  
 5-FU and folinic acid in gastric cancer 850

5-FU and folinic acid in prostatic cancer 644  
 5-FU, prednisone and  $\alpha$ -interferon in renal cell cancer 245  
 MOPP/ABVD in Hodgkin's disease S2: 53  
 m-VAC in breast cancer 93  
 P-VEBEC in elderly patients with lymphoma 895  
 randomized study of 2 combinations in non-small-cell lung cancer 323  
 randomized study of 4 different combinations in aggressive lymphoma (SWOG-8516) S2: 91  
 taxol in combination in breast cancer S6: 23  
 three regimens in the treatment of SCLC 921  
 VACOP-B in mediastinal lymphoma 943  
 VAPEC in lymphoma 147  
 vinorelbine and cisplatin in NSCLC 37

b) single agents

- 2-cDA in CLL and lymphomas 57
- 2-cDA in hairy cell leukemia 676, 725
- 2-cDA in Waldenström macroglobulinemia 288
- cisplatin in mesothelioma 373
- edatrexate in hepatocellular carcinoma 646
- edatrexate in pancreatic cancer 286
- edatrexate in soft-tissue sarcoma 766
- elsamitrucin in breast cancer 375
- elsamitrucin in non-small-cell lung cancer 375
- elsamitrucin in ovarian cancer 375
- epirubicin vs. FU in gastric cancer 33
- etoposide: i.v. or oral in gastric cancer 90
- etoposide in hepatoma 466
- etoposide in mesothelioma 949
- etoposide in ovarian cancer 656
- fludarabine in CLL and lymphomas S2: 79
- gemcitabine in gastric cancer 471
- gemcitabine in lung cancer 283, 852
- gemcitabine in melanoma 471
- in low-grade lymphoma S2: 23
- MGBG in HIV-related lymphoma 487
- oral doxifluridine in colorectal cancer 760
- oral etoposide in hepatomas 466
- oral etoposide in ovarian cancer 656
- paclitaxel and docetaxel 495
- tallimustine: a phase I 901
- taxol in breast cancer 863, S6: 17
- taxol in head-and-neck cancer S6: 51
- taxol in heavily pretreated ovarian cancer 824
- taxol in lung cancer S6: 45
- taxol in multiple myeloma 757
- taxol in ovarian cancer S6: 29, S6: 33, S6: 39, S6: 55
- taxotere in breast cancer 527
- taxotere in colorectal cancer 468
- taxotere in head and neck cancer 533
- taxotere in renal cell cancer 185
- vinorelbine in breast cancer 423, 854
- vinorelbine in HD 817
- weekly 5-FU/CF in gastric cancer 850
- WM26 and carboplatin in SCLC 369

c) general

- and bcl-2 388, S1: 61, S2: 73
- and binding of DNA minor-grooves 877
- and G-CSF 217
- and GM-CSF 43, 709, S2: 123
- chemoradiotherapy 513, 591, 771, S3: 9, S3: 17, S3: 81, S3: 87
- combination chemotherapy vs. cisplatin in head and neck 521
- combined vs. sequential chemoradiotherapy in head-and-neck tumors 513
- combined with chemotherapy in esophageal carcinoma S3: 9, S3: 17
- combined with radiotherapy in SCLC 771, 921
- combined with radiotherapy in stage IIb-IIIa breast cancer 591
- combined with retinoids S9: 17
- efficacy in NSCLC 303
- exacerbation of hepatitis C virus during 861
- in the treatment of extragonadal germ cell tumor 225
- in the treatment of extrapulmonary SCLC 909
- in the treatment of gastric cancer 8, 189
- in the treatment of Hodgkin's disease S2: 17
- in the treatment of low-grade lymphoma S2: 23
- in the treatment of mesothelioma 373, 653, 949
- in the treatment of non-seminomatous germ cell tumors 457
- long term results in melanoma 249
- long term results in SCLC 921
- multidisciplinary treatment of lymphoma S2: 5
- multimodality treatment of pancreatic cancer S3: 81, S3: 87
- new alkylating agents 877, 901
- trial H7 in Hodgkin's disease S2: 107

childhood

- Hodgkin's disease in children S2: 113

chlorambucil

- and prednisone vs. CHOP in low-grade lymphomas S2: 67

2-chlorodeoxyadenosine

- and high incidence of infections 57
- and immunodepression 676
- in CLL 57
- in hairy cell leukemia 676, 725
- in lymphomas 57
- in patients with Waldenström macroglobulinemia 288

CHOP

- vs. CHOP in low-grade lymphoma S2: 67
- vs. mBACOD vs. proMACE-cytaBOM vs. MACOP-B in patients with intermediate or high-grade non-Hodgkin's lymphoma S2: 91

CHVmP-VB

- vs. proMACE-MOPP in intermediate- and high-grade lymphoma S2: 85

cis-retinoic acid (see also retinoic acid)

- and teratogenesis S9: 39
- combined with interferon 391
- pharmacokinetic of S9: 33
- with interferon in squamous carcinomas 463, S9: 29, S9: 33

cisplatin

- and etoposide vs. etoposide-carboplatin in NSCLC 601
- and 5-FU in nasopharyngeal carcinoma 87
- and vinorelbine vs. vinorelbine alone in advanced non-small cell lung cancer 37
- in the combination E-SHAP for lymphoma 453
- intraperitoneally in gastric cancer 123
- vs. combination chemotherapy in head-and-neck tumors 521
- weekly in malignant pleural mesothelioma 373

clinical cases

- male breast cancer 83
- malignant lymphoma vs. sarcoma: discordance between clinical course and immunocytochemistry 365
- management of advanced colorectal cancer 635
- management of desmoid tumours including a case report of toremifene 173
- management of head-and-neck cancer 553
- metastatic tumor of unknown primary site 841
- the endodermal sinus tumour and clear cell ovarian cancer 753
- the management of non-seminomatous germ cell tumours 457
- the management of primary mediastinal B-cell lymphoma with sclerosis 943
- tumour-induced hypoglycaemia: a case report 277

CLL

- and cyclin D1 overexpression S1: 71
- fludarabine-present status and future developments S2: 79
- clonal evolution

  - in relapsing lymphomas S1: 75

- colorectal cancer

  - ADEPT treatment in 879
  - adjuvant therapy of S3: 97
  - and genetics (book) 285
  - management of advanced status 635
  - oral doxifluridine in elderly patients 760
  - phase II trial of elsamitrucin 375
  - protracted venous infusion 5-FU and interferon- $\alpha$  in 239
  - surgery for S3: 91
  - taxotere: a phase II trial 468

- combined modality

  - in early stages of Hodgkin's disease S2: 101
  - in Hodgkin's disease of childhood S2: 113
  - in SCLC 771, 921
  - in squamous cell esophageal carcinoma S3: 9, S3: 17
  - in the management of gastric cancer S3: 37
  - in the treatment of biliary cancer S3: 73
  - of locally advanced pancreatic cancer S3: 81
  - predictive role of Gallium scan after S2: 59
  - preliminary results of H7 protocol for Hodgkin's disease S2: 107
  - the future for the treatment of lymphoma? S2: 5
  - treatment of early and intermediate stages of supradiaphragmatic Hodgkin's disease 809

- common toxicity criteria

  - a comparison with the WHO scoring system for nausea and vomiting 113

- computer modelling

  - and discovery of a new anticancer drug S4: 51

- consensus conference

  - on intensive chemotherapy plus hematopoietic stem cell transplantation in malignancies 19
  - on mantle cell lymphoma 507
  - on GI-lymphoma 397

- continuous infusion

  - of 5-FU compared with bolus 291
  - of 5-FU with epirubicin and cisplatin in gastric cancer 609

- cross-resistance

  - between bolus and continuous infusion of 5-FU 291
  - between taxol and vinorelbine 473

FAC and FEC in breast cancer 95

cytokines

  - and gene transfer in tumor therapy 789
  - a phase I trial of continuous infusion IL-4 alone and following IL-2 447
  - CD30 and its nature 300
  - combined with retinoids S9: 17
  - IL-7, IL-8, and TNF receptor in Hodgkin's disease S1: 93
  - targeting of cytokine gene expression to malignant melanoma cells S4: 59

cytotoxicity assay

  - in vitro drug sensitivity testing using the fluorometric microculture S1: 127

D

data management

  - toxicity grading systems. A comparison between the WHO scoring system and the common toxicity criteria 113

delayed emesis

  - cisplatin-induced delayed emesis 585
  - new directions in research 569
  - ondansetron plus dexamethasone is superior to ondansetron alone 253

desmoid tumours

  - management of 173

dexamethasone

  - combined with granisetron vs. granisetron alone in the prevention of nausea 579
  - in the treatment of cisplatin-induced emesis 585
  - plus ondansetron is superior to ondansetron alone in the prevention of emesis 253
  - to prevent taxol hypersensitivity 474

diet

  - and epidemiology of non-Hodgkin's lymphoma S1: 19

differentiation

  - and CD30 300
  - and retinoids S9: 3, S9: 17
  - involvement of DNA topoisomerases and DNA topoisomerase inhibitors in 679

dipyridamole

  - biochemical modulation of multidrug resistance 733

DNA damage

  - in apoptosis 119
  - with tallimustine 901

DNA ploidy

  - and P53 overexpression in human soft tissue sarcomas 167

DNA topoisomerase

  - involvement in the induction of leukemia cell differentiation 679
  - molecular analysis of topoisomerase II gene in ovarian cancer 75

docetaxel (see also taxotere)

  - an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck 533
  - compared to paclitaxel 495
  - in advanced renal carcinoma 185
  - in metastatic colorectal carcinoma 468
  - in second line treatment for advanced breast cancer 527

dose escalation

  - in breast cancer with G-CSF 217
  - in breast cancer with GM-CSF 43, 709

- in lymphomas S2: 121, S2: 133
- of taxol in ovarian cancer S6: 39
- dose intensity**
  - a study of FLAC and GM-CSF in breast cancer 709
  - and haemopoietic growth factors in aggressive lymphoma S2: 121, S2: 133
  - of taxol in ovarian carcinoma S6: 39
- dose optimization**
  - can be achieved with pharmacokinetic and pharmacodynamic studies S4: 9
  - in the use of suramin 597
  - of tropisetron 821
- doxorubicin**
  - and drug immunotargeting for carcinomas 703
  - cardiac effects following adjuvant treatment in operable breast cancer 209
  - combination chemotherapy with paclitaxel in metastatic breast cancer S6: 23
  - FAC vs. FEC in breast cancer 95
  - indium-111 scintigraphy in diagnosis of cardiotoxicity 617
  - prophylaxis of alopecia 769
- drug design**
  - discovery of new anticancer drugs by computer-aided drug design S4: 51
  - new minor-groove binders 877, 901
- drug resistance**
  - and bcl-2 388, S1: 61
  - in vitro drug sensitivity testing of tumor cells from patients with non-Hodgkin's lymphoma S1: 127
  - molecular analysis of the topoisomerase II- $\alpha$  gene in ovarian cancer 75
  - P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder 835
- drug scheduling**
  - can improve therapeutic results? S4: 9
  - two schedules of etoposide oral or i.v. in ELF 90
- drug screening**
  - and xenografts 396, 415, 877
  - in Europe 396, 415
- DTIC**
  - with thymosin- $\alpha$  1 and IL-2 in patients with metastatic melanoma 741
- dwell-time**
  - its influence in intraperitoneal-administered carboplatin in patients with ovarian cancer 133
- E**
- E-SHAP**
  - in relapsed lymphoma 453
- EBMT**
  - results in ABMT for high-grade lymphoma S2: 155
  - results in ABMT for low-grade lymphoma S2: 147
- edatrexate**
  - in pancreatic carcinoma: a phase II 286
  - in patients with hepatocellular carcinoma: a phase II 646
  - in soft-tissue sarcoma: a phase II 766
- elderly**
  - best treatment for patients with lymphoma 873
  - comparable prognostic factors in patients with aggressive non-Hodgkin's lymphoma S2: 47
  - oral doxifluridine in patients with metastatic colorectal cancer 760
  - P-VEBEC in patients with lymphoma 895
  - weekly carboplatin and VM-26 for patients with SCLC 369
- elsamitrucin**
  - phase II studies in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer 375
- endocrine therapy**
  - formestane as S7: 1, S7: 11
  - goserelin as 337
  - in adjuvant treatment 717
  - of breast cancer 337, 717, S7: 1, S7: 11, S7: 15, S7: 19
  - toremifene in desmoid tumours 173
- endodermal sinus tumour**
  - and its management 753
- endonucleases**
  - and their role in apoptosis 119
- endothelium**
  - and angiogenesis 305, S4: 45
- energy expenditure**
  - after hepatic artery occlusion 961
  - and body composition in the treatment of SCLC 915
- epidemiology**
  - of gastric cancer in Ticino 954
  - of invasive cervical cancer in Vaud, Switzerland 1974-1991 747
  - of non-Hodgkin's lymphoma S1: 19
  - of primary CNS-lymphoma 349
- epidermal growth factor-receptor**
  - and upregulation by 5-aza-2'-deoxycytidine 269
- epirubicin**
  - and cisplatin with 5-FU in gastric cancer 609
  - antitumor activity and toxicity 98
  - FEC for breast cancer 95
  - vs. 5-FU in gastric cancer 33
- Epstein-Barr virus (EBV)**
  - and the interrelationship between Hodgkin's disease and non-Hodgkin's lymphomas S1: 7
- in Hodgkin's disease S1: 105**
- in nasal T-cell lymphoma S1: 39**
- latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non-Hodgkin's lymphomas S1: 113**
- esophageal carcinoma**
  - current status and future directions in the treatment of S3: 27
  - neoadjuvant therapy for S3: 17
  - radiotherapy with or without chemotherapy S3: 9
- etiology**
  - of HIV-related lymphoma S2: 29, S2: 41
  - of Hodgkin's disease S1: 105
  - of nasal lymphoma S1: 39
  - of post-transplant lymphomas S1: 113
- etoposide**
  - chronic oral administration in hepatomas 466
  - chronic oral administration in mesothelioma 949
  - chronic oral administration in ovarian cancer 656
  - combined with carboplatin or cisplatin in NSCLC 601
  - doses and scheduling S4: 25
  - in combination with carboplatin in breast cancer 858

in the combination E-SHAP in lymphoma 453  
 two administrations in gastric cancer 90  
 with ELF in gastric cancer 90  
**euthanasia**  
 a further comment 378  
**extragonadal**  
 malignant germ-cell tumors in females management 225  
**extrapulmonary**  
 small-cell carcinoma: a single-institution experience 909

**F**

**FAC**  
 dose escalation with G-CSF 217  
 only partial cross-resistance with FEC 95

**feasibility**  
 of quality-of-life assessment in an international study 65

**FEC**  
 only partial cross-resistance with FAC 95

**fertility**  
 dose-dependent impairment of testicular function 355

**fever**  
 duration of i.v. antibiotics for neutropenic fever 441

**FISH**  
 and chromosome analysis of non-Hodgkin's lymphomas S1: 51  
 in mantle cell lymphoma 507, S1: 35  
 investigation of activation state of chromosome S1: 47

**flow cytometry**  
 for evaluation of growth-inhibition in follicular lymphomas 265  
 for measuring cell kinetics in ovarian cancer 627

**fludarabine**  
 and immunosuppression S2: 79  
 in the treatment of CLL and lymphoma S2: 79  
 partial cross-resistance with 2-cDA in Waldenström macroglobulinemia 288

**folinic acid**  
 and 5-FU in hormone-refractory prostatic cancer 644  
 and weekly high-dose 5-FU as salvage treatment in advanced gastric cancer 850  
 in the adjuvant therapy of colorectal cancer S3: 97  
 follicular lymphomas (see lymphomas and non-Hodgkin's lymphomas)  
**formestane**  
 in advanced breast cancer S7: 1, S7: 11, S7: 15, S7: 19

**5-FU**  
 and cisplatin in nasopharyngeal carcinoma 87  
 and folinic acid in gastric cancer 850  
 and high-dose folinic acid in prostatic cancer 644  
 and prednisone/α-interferon in renal cell cancer 245  
 comparison bolus/continuous infusion 291  
 doses and scheduling S4: 25  
 in adjuvant treatment for gastric cancer S3: 49  
 in adjuvant treatment of colorectal cancer S3: 97  
 in FAC/FEC for breast cancer 95, 217  
 in multimodality treatment for pancreatic cancer S3: 73, S3: 81  
 vs. epirubicin in gastric cancer 33  
 weekly with folinic acid in gastric cancer 850

**fucosyl-GM**  
 in small-cell lung cancer: a comparison with NSE 623

**G**

**G-CSF**  
 after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation 781, 795  
 and dose intensity in lymphoma S2: 13, S2: 133  
 dose escalation in breast cancer 217, 674  
 supporting dose-escalated doxorubicin and ifosfamide in mesothelioma 653  
 with P-VEBEC in lymphoma 895

**Gallium scan**  
 and magnetic resonance imaging in mediastinal lymphoma 433  
 predicts relapse in Hodgkin's disease S2: 59

**gastric cancer**  
 adjuvant treatment S3: 49  
 ECF chemotherapy for 609  
 ELF chemotherapy for 90  
 epidemiology in Ticino 954  
 epirubicin vs. 5-FU 33  
 etoposide in 2 schedules for 90  
 gemcitabine: a phase II trial 471  
 general principles of chemotherapy 8  
 initial or delayed chemotherapy 189  
 intraperitoneal cisplatin in the management 123  
 preoperative chemotherapy S3: 59  
 role of radiotherapy S3: 37  
 salvage treatment 850  
 strategies in the surgical treatment of S3: 33  
 treatment of localized disease S3: 69  
 treatment with supportive care only? 189  
 weekly high-dose 5-FU and folinic acid 850

**gastro-oesophageal cancer**  
 a phase II study using epirubicin and cisplatin in combination with continuous infusion 5-FU (ECF) 609

**gemcitabine**  
 in extensive SCLC 283  
 in gastric cancer 471  
 in head-and-neck tumors 543  
 in malignant melanoma 471  
 twice weekly in NSCLC 852  
 weekly in bladder cancer 182

**gene amplification**  
 and possible therapeutic approaches 205  
 and retinoids S9: 11  
 and the topoisomerase II-α gene 75  
 in breast cancer S4: 17, S4: 37  
 in soft tissue sarcomas S4: 17

**gene rearrangements**  
 in follicular lymphomas S1: 61  
 in mantle cell lymphomas 507  
 in relapsing lymphomas S1: 75  
 in solid tumors 388

**gene therapy**  
 and inhibition of angiogenesis S4: 45  
 gene transfer in tumor therapy (Review) 789  
 in malignant melanoma cells S4: 59  
 Second International Conference on Gene Therapy of Cancer (Commentary) 313  
 targeting of cytokine gene expression S4: 59

germ-cell tumors  
 and acute monocytic leukemia 649  
 extragonadal malignant germ-cell tumors in females 225  
 ovarian germ-cell tumors 225  
 the management of non-seminomatous germ-cell tumours (GCT) 457

GI-lymphoma  
 treatment of 397  
 workshop on pathological and staging classification 397

GM-CSF  
 a dose intensity study of FLAC chemotherapy and 709  
 after autologous PBPC transplantation 781  
 and dose intensity in lymphoma S2: 13, S2: 133  
 failure to permit dose-escalation in advanced breast cancer 43  
 randomized against placebo with COP-BLAM for lymphomas S2: 123

granisetron  
 alone and in combination with dexamethasone 579  
 new directions in research 569

growth factors  
 conference on 'Growth Factors, Development and Cancer' (Commentary) 575  
 exploiting tumour biology: novel approaches in cancer therapy (Commentary) 205

GVHD  
 and enhanced muco-cutaneous toxicity 377

**H**

Ha-ras  
 oncogene-targeted antisense DNA S4: 55

hairy cell leukemia  
 and 2-cDA 676  
 long-term results of  $\alpha$ -interferon 725  
 treatment of choice 676

head-and-neck cancer  
 a phase II of gemcitabine (LY 188011) 543  
 a randomized study of sequential vs. simultaneous chemoradiotherapy 513  
 and retinoids 463, S9: 17, S9: 23  
 cis-retinoic acid and interferon in the treatment of 463  
 docetaxel: an active drug for 533  
 growth modulation effects of retinoids and interferon on cell lines S9: 7  
 management of 553  
 paclitaxel: a phase II trial S6: 51  
 prevention with retinoids S9: 23, S9: 29  
 randomized comparison of CABO vs. CF vs. cisplatin 521  
 treatment with PEG-IL-2 957

*Helicobacter pylori*  
 and GI-lymphoma 397  
 and the epidemiology of non-Hodgkin's lymphoma S1: 19

hematopoietic stem cell  
 consensus conference on intensive chemotherapy plus hematopoietic stem cell transplantation in malignancies 19  
 durability of autografting 935

hemopoietic growth factors (see also G-CSF and GM-CSF)  
 and dose intensity in high-grade and intermediate-grade lymphoma S2: 123, S2: 131, S2: 133  
 cost-benefit in older patients with non-Hodgkin's lymphoma S2: 127  
 in breast cancer 43, 217, 709

in the treatment of myelodysplastic syndrome 401

hepatic artery  
 occlusion in rat liver tumour 961

hepatitis-C virus  
 acute exacerbation during chemotherapy and radiotherapy 861

hepatocellular carcinoma  
 phase II trial of chronic daily VP-16 466  
 phase II trial of edatrexate 646

high-dose chemotherapy  
 and PBCPs 781, 795  
 and the role of GM-CSF 663  
 dose-escalated doxorubicin and ifosfamide/mesna in malignant mesothelioma 653  
 in breast cancer 43, 217, 674, 709  
 in high-grade lymphoma S2: 123, S2: 131, S2: 133, S2: 155  
 in low-grade lymphoma S2: 143, S2: 147, S2: 151  
 in older patients with lymphoma S2: 127  
 in primary mediastinal lymphoma 943  
 summary of consensus conference 19

high-grade lymphoma (see lymphomas)

histologic transformation  
 and low-grade lymphoma S2: 23  
 and mantle-cell lymphoma 507

identification of genetic lesions associated with S1: 55

HIV  
 and ALL 437  
 and breast cancer 661  
 and etiology of lymphomas S2: 29  
 and HD S2: 37  
 and lymphomas S2: 29, S2: 41  
 lymphomas and prognostic factors S2: 41

Hodgkin's disease  
 CAV as salvage treatment 427  
 clinicopathological features of HIV-related cases S2: 37  
 disseminated growth of cell lines in SCID mice S1: 121  
 early bone marrow transplantation in S2: 161  
 early-stage: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy S2: 101  
 Gallium scan predicts relapse S2: 59  
 Hodgkin's disease in patients with HIV infection 487, S2: 37  
 hybrid LOPP/EVA is not better than LOPP S2: 117  
 IL-7, IL-8 and TNF receptors in the serum of S1: 93  
 interrelationship with non-Hodgkin's lymphomas S1: 7  
 is an infectious disease? S1: 105  
 late mortality in young BNLI patients S2: 65  
 long-term results with the alternating MOPP/ABVD chemotherapy S2: 53  
 MGBG in the treatment of HIV-related cases 487  
 P53 as a marker of the malignant cell S1: 89, S1: 93  
 preliminary results of the trial H7 in early-stage S2: 107  
 prognostic factors in 809, S2: 17, S2: 37, S2: 53, S2: 97, S2: 101  
 proliferation of Reed-Sternberg cells and variants S1: 117  
 radiotherapy in early stages 809, S2: 101, S2: 107, S2: 113  
 review of treatment 1993 S2: 17  
 the quality of life of long-term survivors 153  
 treatment of early and intermediate supradiaphragmatic stages 809  
 vinorelbine: an active drug for 817  
 with a mediastinal mass greater than 10 cm S2: 97

hospice  
 and quality-of-life assessment in palliative care 13

5-HT3 receptor antagonist  
 a phase I study of MDL 73,147EF 549  
 granisetron alone or in combination 579  
 new directions in research 569  
 ondansetron alone or in combination 98, 253  
 tropisetron: a dose finding study 821

HTLV-1  
 and lymphokine receptors S1: 13

hybrid chemotherapy  
 four drug combinations in aggressive lymphomas S2: 91  
 hCHOP/iVEP in high-grade lymphoma 49

LOPP/EVA is not better than LOPP alternating with EVAP S2: 117  
 VAPEC-B in high-grade lymphomas 147

hypercalcaemia  
 dose of pamidronate 359, S7: 45  
 pamidronate in the treatment of tumour-induced 359

hypersensitivity reactions  
 with docetaxel 185  
 with paclitaxel 474, 827

hypoglycaemia  
 tumour-induced (Clinical cases) 277

**I**

ifosfamide  
 dose escalated with doxorubicin in mesothelioma 653  
 or cisplatin in combination for NSCLC 159

IL-2  
 and gene transfer 789  
 and release of IL-8 929  
 biology of 119, 789, S1: 113  
 in renal cell cancer 179  
 with IL-4: a phase I study 447  
 with thymosin- $\alpha$  and dacarbazine in melanoma 741

IL-3  
 growth inhibition of follicular small-cleaved-cell lymphoma cells 265

IL-4  
 in the serum of patients with Hodgkin's disease S1: 93

IL-7  
 in the serum of patients with Hodgkin's disease S1: 93

IL-8  
 and treatment with IL-2 929  
 in the serum of patients with S1: 93

immune response  
 and aetiology of HD S1: 105

immunoconjugates  
 a reality at last? 703  
 and future perspectives 697  
 lessons from animal models 698

immunodeficiency  
 and EBV S1: 113  
 and Hodgkin's disease S2: 37  
 and lymphoproliferative disorders S1: 113, S2: 29, S2: 41  
 and the interrelationship between Hodgkin's disease and non-Hodgkin's lymphomas S1: 7  
 and lymphoma S2: 29

immunohistochemistry

analysis of the *P53* gene in non-Hodgkin's lymphomas S1: 85  
 lymphoma vs. sarcoma (Clinical cases) 365  
 P53 in Hodgkin's disease S1: 89  
 prognostic value of cathepsin D expression in breast cancer: immunohistochemical assessment and correlation with radiometric assay of cathepsin D 329

immunotargeting  
 for anticancer drugs 703

immunotherapy  
 and gene transfer 789  
 IL-2 in renal cell cancer 179  
 IL-2, thymosin- $\alpha$  and dacarbazine in melanoma 741  
 IL-4 and IL-2: a phase I study 447  
 lymphokine receptors as a target of S1: 13  
 PEG-IL2 treatment of head-and-neck tumors 957

immunotoxins  
 is there a clinical value? S1: 97

<sup>111</sup>In-antimyosin  
 usefulness in confirming myocardial injury with anthracycline-associated left ventricular dysfunction 617

incidence  
 of gastric lymphoma in Ticino 954  
 of invasive cervical cancer in Vaud, Switzerland, 1974-1991 747  
 of non-Hodgkin's lymphoma S1: 19  
 of primary central nervous system 349

infection  
 high incidence after 2-chlorodeoxyadenosine 57

insul-like growth factors  
 tumour-induced hypoglycaemia (Clinical cases) 277

interferon(s)  
 and 5-FU in colorectal cancer 239  
 and prednisone in renal cell cancer 245  
 anosmia associated with 863  
 combination with retinoids 391  
 in combination with chemotherapy in lymphoma S2: 73  
 in the treatment of hairy cell leukemia 676, 725  
 with 13-cis-retinoic acid in squamous carcinomas 463  
 with retinoids in general S9: 3, S9: 7, S9: 33

intermediate cell lymphoma (see mantle cell lymphoma)

intraperitoneal treatment  
 and dwell-time 133, 662  
 future prospects 108  
 in gastric cancer 123  
 in patients with ovarian cancer 127, 133, 343, 662, S6: 55  
 with carboplatin 127, 133, 662  
 with mitoxantrone 343  
 with taxol S6: 55

ischaemia  
 and hepatic artery occlusion in rat liver tumour 961

isochromosome  
 and acute monocytic leukemia occurring in mediastinal germ cell tumour 649

**K**

Ki-1 lymphoma  
 a distinct clinicopathologic entity S1: 25, S1: 31  
 and CD30 expression 300  
 in childhood S1: 31

long-term prognostic importance of antigen expression and anaplastic morphology in 317

**Ki-67**  
and proliferation of Reed-Sternberg cells and variants in Hodgkin's disease S1: 117

**L**  
**lenograstim (see G-CSF)**  
**lentaron (see formestane)**  
**leukemia**  
and acute lysis syndrome 379  
and lymphomas 689  
and primary mediastinal germ cell tumour 649  
and regulation of chemoresistance by the bcl-2 oncogene S1: 61  
heterogeneity of ALL in HIV-patients 437  
possible treatment by immunotoxins S1: 97  
treatment of secondary leukemias 401

**levamisole**  
in the adjuvant therapy of colon adenocarcinoma S3: 97

**Leydig cell function**  
dose-dependent impairment of function in patients treated with cisplatin 355

**LH-RH analogs**  
ovarian ablation vs. goserelin with or without tamoxifen in advanced breast cancer 337

**limited sampling model**  
for topotecan pharmacokinetics 259  
general principles S4: 9, S4: 67

**low-grade lymphoma (see lymphomas)**

**lung cancer (see also non-small-cell, small-cell lung cancer)**  
a four drug combination in NSCLC 641  
a randomized trial of 3 combinations in SCLC 921  
comparison of MVP vs. MIP in NSCLC 323  
efficacy of chemotherapy in NSCLC 303  
etoposide and carboplatin or cisplatin in SCLC 601  
extrapulmonary small-cell cancer 909  
gemcitabine in SCLC 283  
interferon and cis-retinoic acid in the treatment of 463  
low dose radiotherapy in SCLC 771  
NSE compared to fucosyl-GM<sub>1</sub> in SCLC 623  
phase I study of somatuline 290  
phase II of elsamitrucin in NSCLC 375  
phase II of gemcitabine in NSCLC 852  
taxol in the treatment of S6: 45  
vinorelbine alone or with cisplatin: a randomized trial in NSCLC 37  
weekly carboplatin and VM-26 for elderly with SCLC 369

**lymphokine**  
receptors as a target for immunotherapy S1: 13

**lymphoma**  
ABMT as consolidation for follicular lymphoma S2: 143  
ABMT in the treatment of S2: 143, S2: 147, S2: 151, S2: 155  
anaplastic large-cell lymphoma 300, 317, S1: 25, S1: 31  
and biology of bcl-2 199, S1: 61  
and immunotoxins S1: 97  
bcl-1 by mantle cell 507, S1: 51, S1: 71  
2-cDA in lymphoma 57  
chlorambucil vs. CHOP in low-grade S2: 67  
CHOP vs. 3 other combinations S2: 91

CHOEP vs. alternating hCHOP/iVEP in aggressive forms 49  
comparison of ABMT and PCBP in S2: 151  
differentiation vs. sarcomas 365  
dose intensity and CSFs S2: 131, S2: 133  
EBMT experience with ABMT in high-grade S2: 155  
EBMT experience with ABMT in low-grade S2: 147  
EBV in aetiology of S1: 7, S1: 39, S1: 105, S1: 113  
elderly patients and lymphoma 873  
epidemiology of S1: 19  
fludarabine in lymphoma S2: 79  
genetic lesions associated with S1: 55, S1: 61  
growth inhibition of follicular small-cleaved-cell by IL-3 265  
in children S1: 31  
in immunodeficiency S2: 29  
low-grade: state-of-the-art S2: 23  
MACOP-B in the treatment of S2: 91  
mediastinal B-cell with sclerosis 943  
modern treatment of 689, S2: 5  
nasal T-cell S1: 39  
primary mediastinal lymphoma 847, 943  
prognostic factors in 49, 689, 873, S2: 47, S2: 91  
prognostic factors in HIV-related lymphoma S2: 45  
P-VEBEC for elderly patients 895  
pro-MACE-MOPP vs. CHVmp-VB in S2: 85  
quantitation of cells carrying t(14;18) S1: 43  
randomized comparison of 4 drug combinations (SWOG-8516) S2: 91  
recent progress in (Commentary) 689  
regulation of chemoresistance by the bcl-2 oncogene in S1: 61  
relationship with Hodgkin's disease S1: 7  
reversion to negative of peripheral blood bcl-2 rearrangement S2: 73  
therapeutic use of antisense in S1: 67  
treatment of low-grade S2: 23, S2: 67  
VACOP-B in mediastinal lymphoma 943  
weekly VAPEC-B in aggressive lymphoma 147

**lymphomatoid granulomatosis**  
as a nasal T-cell lymphoma S1: 39

**M**

**m-BACOD**  
compared to CHOP, ProMACE-cytarabine and MACOP-B S2: 91

**M-VAC**  
in locally advanced, locally recurrent or metastatic breast carcinoma 93

in primary and metastatic transitional cell carcinoma of the bladder 835

**MACOP-B**  
compared to CHOP, mBACOD and proMACE-cytarabine S2: 91

**magnetic resonance imaging**  
and Gallium scan in lymphoma 433  
in radiological imaging related to oncology S4: 3

**male breast cancer**  
and its management (Clinical cases) S4: 3

**mantle-cell lymphoma**  
bcl-1 rearrangement in 507, S1: 71  
clinical-pathologic basis S1: 35  
consensus paper on 507  
cyclin D1 overexpression in S1: 71

**MDR**

- amiodarone to overcome it 659
- modulation by BiBW22BS 733
- P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder 835
- mechanism of action
  - of DNA minor-groove binders 877
  - of docetaxel 495
  - of formestane S7: 1
  - of MGBG 487
  - of paclitaxel 495, S6: 3
  - tallimustine 877, 901
- mediastinal mass
  - and Gallium-scan 433, S2: 59
  - and magnetic resonance 433
  - greater than 10 cm in Hodgkin's disease S2: 97
  - in primary mediastinal lymphoma 847, 943
- medical practice
  - and specialized oncologic information 773
- medullary carcinoma
  - chemotherapy with dacarbazine and 5-FU 763
- melanoma
  - and release of IL-8 during IL-2 treatment 929
  - biochemotherapy with thymosin- $\alpha$ 1, IL-2 and dacarbazine 741
  - clinical prognostic significance of tumour angiogenesis 305
  - long term response to chemotherapy 249
  - phase II of gemcitabine 471
  - phase II study of intermittent continuous infusion of low-dose IL-2 179
- menstrual cycle
  - and timing of breast cancer surgery 29
- mesothelioma
  - a phase II of escalated doxorubicin and ifosfamide/mesna 653
  - and CNS involvement 660
  - treatment with oral etoposide 949
  - treatment with weekly cisplatin 373
- metoclopramide
  - compared to oral granisetron alone and in combination with dexamethasone 579
  - in cisplatin-induced delayed emesis 585
- MGBG
  - teaching an old drug new tricks (Special article) 487
- microtubules
  - and mechanisms of action of docetaxel 495
  - and mechanisms of action of paclitaxel 495, S6: 3
- minor-groove binders
  - a new group of alkylating agents (Editorial) 877
  - and DNA damage with the novel distamycin derivative tallimustine 901
- minoxidil
  - as a prophylaxis of doxorubicin-induced alopecia 769
- mitoxantrone
  - intraperitoneal in refractory ovarian cancer: a phase I/II study 343
- molecular biology
  - and breast cancer S4: 17, S4: 31
  - and lymphoma S1: 1
  - and soft-tissue sarcoma S4: 17
  - novel approaches in cancer therapy (Commentary) 205
- monoclonal antibody
  - and ADEPT therapy 879
  - and immunotargeted chemotherapy for carcinomas 698, 703
  - and immunotoxins in the treatment of lymphoma S1: 97
  - 5-aza-2'-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells 269
  - conjugated with enzymes 879
  - drug immunotargeting for carcinomas: a reality at last? 703
  - immunoconjugates: lessons from animal models 698
- MOPP
  - long-term results and prognostic factors S2: 53
- morphine
  - oral tramadol and morphine for strong cancer-related pain 141
- MRI (see magnetic resonance imaging)
- multidrug resistance (see MDR)
- multiple myeloma
  - primary therapy with paclitaxel 757
- mutation
  - of the p53 gene in non-Hodgkin's lymphomas S1: 85
- myeloablative therapy (see ABMT)
- myelodysplastic syndrome
  - new treatment approaches for 401
- N**
- nasal lymphoma
  - clinical-pathological findings S1: 39
- nasopharyngeal carcinoma
  - a phase II trial of 5-FU and cisplatin in 87
- natural killer cells
  - and CD30 300
  - and lymphokines S1: 13
  - and nasal T-cell lymphoma S1: 39
  - in Hodgkin's disease S1: 93
- nausea
  - dose-finding study of tropisetron 821
  - new directions in research 569
  - ondansetron plus dexamethasone is superior to ondansetron alone 253
  - oral granisetron alone or in combination 579
  - toxicity grading systems 113
- navelbine (see vinorelbine)
- neo-adjuvant chemotherapy
  - and radiotherapy in stage IIb-IIIa breast cancer 591
  - for esophageal carcinoma S3: 9, S3: 17, S3: 27
  - in the management of head and neck cancer 553
- neuroendocrine tumours
  - dacarbazine and 5-FU in advanced medullary thyroid cancer 763
- neurotoxicity
  - and taxol/vinorelbine 473
- nitric oxide
  - significantly reduced salivary levels in smokers 371
- non-Hodgkin's lymphoma (see also lymphomas)
  - ABMT for high-grade S2: 151, S2: 155
  - ABMT for low-grade S2: 143, S2: 147
  - 2-cDA in the treatment of 57
  - chromosome analysis by fluorescence in situ hybridization S1: 51
  - dose intensity and CSFs S2: 131, S2: 133
  - EBV in aetiology of S1: 7, S1: 39, S1: 105, S1: 113
  - epidemiology of S1: 19

fludarabine in the treatment of S2: 79  
 haemopoietic growth factors and dose intensity in S2: 133  
 high incidence of infections after 2-CDA 57  
 incidence, clinicopathological features and outcome of primary central nervous system lymphomas 349  
 mantle-cell lymphoma 507, S1: 35, S1: 71  
 multiclonality and altered RFLP patterns for immunoglobulin heavy-chain and T-cell receptor genes in relapsing cases S1: 75  
 pathological and staging classifications of GI-tract lymphoma 397  
 prognostic factors in 49, 689, S2: 47, S2: 91  
 relationship with Hodgkin's disease S1: 7  
 treatment of low-grade S2: 23, S2: 67  
 non-small-cell lung (see also lung cancer)  
     a four drug combination in the treatment of 641  
     efficacy of chemotherapy (Editorial) 303  
     MVP vs. MIP in the treatment of 323  
     phase II studies of elsamitrucin 375  
     phase II study of gemcitabine 852  
     taxol in the treatment of S6: 45  
     vinorelbine vs. vinorelbine plus cisplatin 37  
 NSE  
     vs. fucosyl-GM<sub>1</sub> in small-cell lung cancer 623  
 nude mice  
     in drug screening 396, 415

**O**  
 oncogenes  
     and angiogenesis 305, S4: 45  
     and apoptosis 119  
     and breast cancer S4: 31  
     and gene therapy 313, 789  
     and regulation of chemoresistance S1: 61  
     and retinoids S9: 11  
     bcl-1 in mantle cell lymphoma 507, S1: 35, S1: 71  
     bcl-2 in solid tumours 388  
     in large cell lymphoma S1: 55  
     in the design of new anticancer drugs S4: 55  
 ondansetron  
     plus dexamethasone is superior in the prevention of emesis 253  
     severe vascular adverse effects after 98  
 oophorectomy  
     vs. goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer 337  
 opioids  
     in the fight against pain (Editorial) 111  
     oral tramadol and morphine for strong cancer-related pain 141  
 oral  
     etoposide 90, 466, 656, 949, S4: 25  
     granisetron alone and in combination with dexamethasone 579  
 ovarian carcinoma  
     cell kinetics of human cell lines 627  
     intraperitoneal administration of carboplatin 127, 133  
     intraperitoneal administration of mitoxantrone 343  
     intraperitoneal administration of taxol S6: 55  
     phase II of elsamitrucin 375  
     phase II of oral etoposide 656  
     phase II of taxol S6: 29, S6: 33, S6: 39, S6: 51  
     principles of intraperitoneal therapy 108, 662  
     role of dwell-time for intraperitoneal therapy 133, 662  
     taxol in heavily pretreated patients 824  
     topoisomerase II- $\alpha$  gene and its expression in 75  
     uncommon varieties 753  
 ovarian tumours  
     endodermal sinus tumour and clear cell cancer 753  
     ovarian and extragonadal malignant germ-cell tumors in females 225

**P**  
 p-glycoprotein  
     expression in carcinoma of the bladder 835  
     modulation by amiodarone 659  
     modulation by BIBW22BS 733  
 P-VEBEC  
     with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma 895  
 p53  
     a marker of the malignant cell in Hodgkin's disease S1: 89  
     and apoptosis 119  
     in diffuse large-cell lymphoma S1: 55  
     its expression and protein stabilization in non-Hodgkin's lymphomas S1: 85  
     overexpression in human soft tissue sarcomas 167  
     protein levels are elevated in the serum of patients with Hodgkin's disease S1: 93  
 paclitaxel (see taxol)  
 pain control  
     oral tramadol and morphine for 141  
     pamidronate in the palliation of bone metastases S7: 31, S7: 37, S7: 41  
     the fight for 111  
 palliative care  
     quality assessment in 13  
 pamidronate  
     and mechanical properties of canine bone S7: 49  
     and tumour-induced hypercalcaemia 359  
     delayed progression of bone metastases with S7: 41  
     dose-response relationship 359  
     in palliation of advanced breast cancer S7: 45  
     in the management of bone metastases from breast cancer S7: 37  
     in the treatment of bone metastases S7: 31  
     i.v. administration: infusion rate and safety S7: 27  
     mechanism of action S7: 25  
     to modulate fracture repair in ovine bone S7: 53  
 pancreatic cancer  
     future directions in the perioperative treatment of S3: 87  
     multimodality treatment of locally advanced S3: 81  
     phase II trial of edatrexate 286  
     surgery of S3: 73  
 paraneoplastic  
     treatment of tumour-induced hypercalcaemia with pamidronate 359  
 patient information  
     and palliative care 13  
     and quality-of-life assessment 95  
     in the cancer consultation 199  
 pazelliptine  
     in preclinical phase II studies in human tumor xenografts 415  
 pediatric lymphomas  
     summary of recent advances S1: 31

**PEG-IL-2**

- intratumoral therapy in locoregionally recurrent head and neck carcinoma 957

**perioperative treatment**

- in colorectal carcinoma S3: 115
- in localized esophageal cancer S3: 27
- in localized gastric cancer S3: 69
- in rectal cancer S3: 105

**peripheral blood progenitor cell support**

- and CD34+ cells 935
- comparison with ABMT S2: 151
- effect of graft-size 781, 795, 935
- how many cells are needed? 781, 935
- in breast cancer 217
- long-term durability of hematopoiesis after 935
- summary of consensus paper on 19

**pesticides**

- their role in the epidemiology of non-Hodgkin's lymphoma S1: 19

**pharmacokinetic(s)**

- and improvement of phase I clinical trials S4: 67
- and the problem of doses and scheduling S4: 25
- can improve cancer chemotherapy? S4: 9
- limited sampling models for topotecan 259
- of oral etoposide 90, 656
- of paclitaxel in brain tumours 951
- of paclitaxel, including metabolism S6: 7
- of retinoids S9: 33
- of suramin for breast and prostate cancer 597
- of tallimustine 901

**phase I trials**

- and its methodology S4: 67
- of intraperitoneal mitoxantrone in refractory ovarian cancer 343
- of somatuline in SCLC 290
- of tallimustine 901
- of weekly gemcitabine in advanced bladder cancer 182

**phase II trials of**

- cisplatin in mesothelioma 373
- elsamitruclin in breast cancer 375
- elsamitruclin in colorectal cancer 375
- elsamitruclin in ovarian cancer 375
- gemcitabine in gastric cancer 471
- gemcitabine in head-and-neck tumors 543
- gemcitabine in melanoma 471
- gemcitabine in small-cell lung cancer 283
- intraperitoneal mitoxantrone in refractory ovarian cancer 343
- oral etoposide in hepatomas 466
- oral etoposide in mesothelioma 949
- oral etoposide in ovarian cancer 656
- taxotere in breast cancer 527
- taxotere in colorectal cancer 468
- taxotere in head-and-neck tumors 533
- taxotere in renal cell cancer 185
- vinorelbine in breast cancer 423, 854
- vinorelbine in HD 817
- weekly i.v. vinorelbine in first-line advanced breast cancer 854

**platinum (see cisplatin, carboplatin)**

**pollution**

- and human cancer (book) 195

**polyamines**

- and their role in apoptosis 119

**MGBG: an important derivative 487**

**positron emission tomography**

- in radiological imaging related to oncology S4: 3

**potential doubling time**

- and cell kinetics of human ovarian cancer 627

**PRADI**

- and cyclin D1 overexpression in non-Hodgkin's lymphoma S1: 71

**preclinical models**

- and immunoconjugates 698
- and phase II studies 415

**prednisone**

- with interferon- $\alpha$  and 5-FU in metastatic renal cell carcinoma 245

**prevention**

- and cervical cancer 747
- and retinoids S9: 23, S9: 29

**prodrug(s)**

- in antibody directed enzyme therapy for cancer 879

**prognostic factors in**

- angiogenesis 305
- breast cancer of cathepsin D 329
- CD30+ lymphoma 317
- CNS lymphoma 349
- elderly patients with lymphoma 873, 895, S2: 47
- extragonadal female tumors 225
- HIV-related lymphoma S2: 45
- Hodgkin's disease S1: 93, S2: 97, S2: 107
- large cell lymphomas 49, 689, S2: 47, S2: 91
- malignant melanoma 249
- ovarian cancer 75, 627
- primary mediastinal lymphoma 847

**proliferation**

- and retinoids S9: 7, S9: 17, S9: 23
- of human ovarian cell lines 627
- of Reed-Sternberg cells and variants S1: 117

**proMACE-cytarBOM**

- compared to CHOP, mBACOD and MACOP-B in non-Hodgkin's lymphoma S2: 91

**proMACE-MOPP**

- compared to CHVmP-VB in patients with aggressive lymphoma S2: 85

**prostatic cancer**

- 5-FU and high-dose folinic acid in hormone-refractory 644
- pamidronate in the treatment of bone metastases from S7: 31
- suramin for 597

**Q**

**quality of life**

- assessment in palliative care 13
- in long-term survivors of Hodgkin's disease 153
- timing of assessment in adjuvant treatment for breast cancer 65

**R**

**radiosensitizer**

- all-trans-retinoic acid as S9: 3, S9: 7
- taxol as S6: 3

**radiotherapy**

after chemotherapy in advanced lymphoma 49  
 after chemotherapy in SCLC 921  
 and angiosarcoma of the residual breast 163  
 combined with chemotherapy in Hodgkin's disease S2: 17  
 combined with primary chemotherapy or alone in stage IIb-IIIa breast cancer 591  
 following neoadjuvant therapy for squamous cell esophageal carcinoma S3: 17  
 for extrapulmonary SCLC 909  
 in low-dose for small-cell lung cancer 771  
 in the management of desmoid tumours 173  
 in the management of gastric cancer S3: 37  
 in the multimodality treatment of lymphoma S2: 5  
 in the treatment of early stages of HD 809, S2: 5, S2: 101, S2: 107, S2: 113  
 in the treatment of GI-lymphoma 397  
 in the treatment of Hodgkin's disease in children S2: 113  
 with or without concomitant chemotherapy for esophageal carcinoma S3: 9

**RAR**  
 and angiogenesis S9: 17  
 and retinoids S9: 11, S9: 23  
 and transcription factors S9: 11, S9: 23

**reconstructive surgery**  
 current controversies in the surgical management of breast cancer S4: 39

**rectal cancer**  
 perioperative radiotherapy ± chemotherapy in S3: 105  
 phase II of docetaxel in colorectal cancer 468

**Reed-Sternberg cells**  
 proliferation of Hodgkin's disease S1: 117

**renal cell cancer**  
 α-interferon, 5-FU and prednisone in the treatment of 245  
 and i.v. bolus IL-2 929  
 IL-8 release during IL-2 treatment 929  
 phase II intermittent continuous infusion of low-dose recombinant IL-2 179  
 phase II of docetaxel 185

**renal function**  
 and taxanes 495  
 in the case of i.v. pamidronate: infusion rate and safety S7: 27

**repair mechanisms**  
 in the mechanism of action of fludarabine S2: 79

**retelliptine**  
 preclinical phase II studies in human tumor xenografts 415

**retinoic acid**  
 and angiogenesis S9: 17  
 and differentiation S9: 3, S9: 11, S9: 23  
 and growth-inhibition S9: 7  
 and molecular mechanisms S9: 11, S9: 17  
 and radiation in cell lines S9: 3, S9: 7  
 and transcription factors S9: 11, S9: 17  
 combined with chemotherapy S9: 17  
 combined with cytokines and vitamin D analogs S9: 17  
 in prevention S9: 23, S9: 29  
 in the treatment of squamous cell cancers 463, S9: 17, S9: 23, S9: 29, S9: 33  
 inhibition of metabolism by liarozole-fumarate S9: 45

metabolism of S9: 45  
 pharmacokinetic of S9: 33, S9: 39, S9: 45  
 teratogenesis of S9: 39

**Review**  
 antibody directed enzyme prodrug therapy 879  
 chemoprophylaxis of fungal infections in neutropenic patients 571  
 clinical prognostic significance of tumour angiogenesis 305  
 gene transfer in tumor therapy 789  
 involvement of DNA topoisomerases and DNA topoisomerase inhibitors in the induction of leukemia cell differentiation 679  
 new treatment approaches for myelodysplastic syndrome and secondary leukaemias 401  
 paclitaxel and docetaxel: not simply two of a kind 495

**S**

**saliva**  
 significantly reduced nitric oxide levels in smokers in 371

**salvage chemotherapy**  
 CAV in Hodgkin's disease 427  
 E-SHAP in selected patients with non-Hodgkin's lymphoma 453  
 vinorelbine in Hodgkin's disease 817  
 weekly high-dose 5-FU and folinic acid in gastric cancer 850

**sarcoma**  
 and tumour-induced hypoglycaemia 277  
 application of molecular genetics and cytogenetics to S4: 17  
 vs. malignant lymphoma 365

**SCID mouse**  
 disseminated growth of Hodgkin's-derived cell lines L540 and L540cy in S1: 121

**screening**  
 and long-term results in invasive cervical cancer in Vaud, Switzerland 747

**second look**  
 after intraperitoneal carboplatin in ovarian carcinoma 127

**second malignancies**  
 after adjuvant treatment 785  
 and enhanced muco-cutaneous toxicity 377  
 following CMF-based adjuvant chemotherapy 803  
 treatment of secondary leukemias 401

**small-cell lung cancer (see also lung cancer)**  
 and body composition during treatment 915  
 and energy expenditure during treatment 915  
 chest irradiation in the treatment of 921  
 extrapulmonary forms 909  
 fucosyl-GM and NSE in 623  
 gemcitabine in advanced cases 283  
 gemcitabine in untreated patients 283  
 low-dose radiotherapy 771  
 phase I of somatuline 290  
 randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation 601  
 randomized comparison of 3 regimens of chemotherapy 921  
 weekly carboplatin and VM-26 for elderly patients 369

**smoking**  
 and reduced salivary nitric oxide levels in 371

**soft tissue sarcoma**  
 and molecular genetics S4: 17  
 phase II trial of 10-EDAM in 766

**solvents**  
 and their role in the epidemiology of non-Hodgkin's lymphoma S1: 19

**somatostatin**  
 in SCLC 290

**spermatogenesis**  
 dose-dependent impairment of testicular function in patients treated with cisplatin 355

**splenectomy**  
 long-term results of its use as consolidation therapy in patients with hairy cell leukemia 725

**squamous cell carcinoma**  
 efficacy of recombinant  $\alpha$ -interferon 2a and 13-cis-retinoic acid in the treatment of 391, 463

growth modulation of  $\alpha$ -interferon and ionizing radiation in cell lines S9: 7

retinoids in prevention of S9: 23, S9: 29

retinoids in treatment of S9: 29

**staging**  
 of gastrointestinal tract lymphoma 397

**supportive care (see also palliative care)**  
 in gastric cancer 189

in tumour-induced hypercalcaemia 359

**suramin**  
 for breast and prostate cancer 597

**surgery**  
 for cancer of the colon and rectum S3: 91

for squamous cell esophageal carcinoma S3: 1, S3: 17

in the management of desmoid tumours 173

in the treatment of localized gastric cancer S3: 33, S3: 69

in the treatment of pancreatic cancer S3: 87

of pancreatic cancer S3: 73

reconstructive in breast cancer S4: 39

timing of, in breast cancer 25, 29

**T**

**t(11;14) (q13;q32)**  
 in non-Hodgkin's lymphoma S1: 71

**t(14;18) (see also bcl-2)**  
 quantitation of cells carrying t(14;18) before and after allogeneic bone marrow transplantation S1: 43

**T-cell**  
 and anaplastic large-cell lymphoma S1: 25, S1: 31

and their receptors in relapsing lymphomas S1: 75

in nasal lymphoma S1: 39

recent progress in B- and T-cell lymphomas (Commentary) 689

**tallimustine**  
 as an example of a new class of alkylating agents (Editorial) 877

phase I study of 901

**tamoxifen**  
 comparison with formestane as first-line hormonal therapy in postmenopausal women S7: 19

in adjuvant chemo-hormone therapy for breast cancer 717

with ovarian ablation or goserelin in pre-perimenopausal patients with advanced breast cancer 337

**targeting**  
 and 5-aza-2'-deoxycytidine 269

and new therapeutic options 575

antibody directed enzyme prodrug therapy 879

**taxoids**  
 comparison of paclitaxel and docetaxel 495

**taxol (see also paclitaxel)**  
 and hypersensitivity reaction 474

and neurotoxicity 473

and tissue concentration in brain tumours 951

and vinorelbine: cross-resistance? 473

carboplatin and taxol in advanced ovarian carcinoma S6: 39

clinical pharmacology and metabolism of taxol: update 1993 S6: 7

combination chemotherapy in breast cancer S6: 23

future directions S6: 59

in heavily pretreated ovarian cancer 824

in the treatment of ovarian cancer S6: 29, S6: 33, S6: 39, S6: 51, S6: 55

intraperitoneally S6: 55

mechanism of action S6: 3

pharmacology of S6: 17

phase II in breast cancer S6: 17, 863

phase II in head and neck tumors S6: 51

phase II in lung cancer S6: 45

phase II in multiple myeloma 757

preoperatively in breast cancer 863

review of phase II trials in patients with advanced ovarian cancer S6: 29

safety in patients with platinum pretreated ovarian carcinoma S6: 33

**taxotere**  
 in advanced renal carcinoma 185

in breast cancer 527

in head and neck cancer 533

in metastatic colorectal carcinoma 468

**teniposide**  
 and weekly carboplatin for elderly patients with small-cell lung cancer 369

**teratogenesis**  
 of retinoids S9: 39

**testicular cancer**  
 and dose-dependent impairment of testicular function 355

management of 457

**therapy related**  
 myelodysplastic syndrome and secondary leukaemias 401

**thymic cells**  
 and apoptosis 119

**thymosin- $\alpha$ 1**  
 with IL-2 and dacarbazine in metastatic melanoma 741

**time trends**  
 in incidence, mortality and survival from invasive cervical cancer 747

in incidence of gastric cancer 954

**timing**  
 of breast cancer surgery during the menstrual cycle 29

**tissue concentration**  
 of paclitaxel in brain tumor tissue 951

**TNF receptor**  
 in the serum of patients with Hodgkin's disease S1: 93

**topoisomerase**  
 gene expression in human ovarian cancer 75

involvement in the induction of leukemia cell differentiation 679

**topotecan**  
 limited sampling models for 259

**toremifene**

in the management of desmoid tumours 173

**toxicity**

after intraperitoneal chemotherapy 133

grading systems for nausea and vomiting 113

high incidence of infections after 2-cDA 57

hypersensitivity with taxol 474, 495

long term of adjuvant treatment 196, 209

mucocutaneous in GHVD 377

neurotoxicity after taxol 473

of anthracyclines 617

of ondansetron 98

too high in the treatment of lung cancer 323

**tramadol**

for strong cancer-related pain 141

**tropisetron**

dose-finding study in cisplatin-induced nausea and vomiting 821

**tumor-suppressor gene**

and apoptosis 119

and cancer biology 575

in breast cancer S4: 31

P53 in Hodgkin's disease S1: 89, S1: 93

P53 in NHL S1: 85

P53 in soft tissue sarcoma 167

**U****ultrasound**

in radiological imaging related to oncology S4: 3

**unknown primary tumor**

(Clinical case) 841

**V****VACOP-B**

in primary mediastinal lymphoma 943

**VAPEC-B**

VAPEC-B chemotherapy for high-grade NHL 147

**verapamil**

and biochemical modulation of 733

**vinorelbine**

alone vs. combined with cisplatin in advanced non-small-cell lung cancer 37

as a salvage treatment for advanced breast cancer 423

for the management of patients with heavily pretreated Hodgkin's disease 817

in first-line advanced breast cancer chemotherapy 854

**vomiting (see antiemetics)****VP-16 (see etoposide)****vitamin D analogs**

and retinoids S9: 17

**W****Waldenström macroglobulinemia**

2-chlorodeoxyadenosine therapy of 288

**WHO**

toxicity grading systems 113

**X****X chromosome**

the activation state in non-Hodgkin's lymphomas S1: 47

**xenografts**

and drug screening 396, 415

and preclinical phase II studies 415

## Index of authors Volume 5 (1994)

---

(Abstract Supplements 5 and 8 not included)

<b>A</b>		
Aamdal S 471	Babare R S2: 127	Bicknell R S4: 45
Aapro MS 253, 369, 964	Babilonti L 627	Bier H 957
Aaronson NK 113, 153	Bacchi M 253	Birkmann J 49
Aartsen E 343	Badri N 37	Biron P 95
Aas M 433	Badwe RA 29	Bisagni G 93
Abbruzzese JL 286, 468	Bagshawe KD 879	Bittar C 772
Abdel-Warith A 453, 466	Bajetta E S7: 15	Björkholm M 571, S2: 67
Abdulkareem M 466	Baldini L 725	Björkstrand B S2: 147
Abeloff MD 43	Balestremo M 337	Blaise D S2: 155
Acito A S7: 49	Balzarini L 817	Blanchon F 37
Adenis A 423	Bamberg M 377, S9: 3, S9: 7	Blanco E 323
Aglietta M 663	Bamberger U 733	Bleehen NM 915
Aitini E 463	Banik N S1: 121	Bleher EA 921
Aitken SE 644	Barakat R S6: 55	Bleiberg H 821
Ajani JA 286, 468, S3: 9, S3: 75	Barash NY 591	Bliss JM 33
Al-Bahar E 379	Barbieri M 769	Boccardo F 337
Al-Bahar S 379	Barduagni M 760	Bochtler H S3: 17
Alakl M 527	Bartoli C S7: 15	Bodis S 371
Alberola Candel V S7: 19	Barzan L 553, 909	Bodmer JG S1: 117
Alberto P 369, 771, 921	Bastian A 709	Bodurtha A 766
Alessandrino EP 427, S2: 101	Bastion Y 437	Body JJ 359
Alexanian R 288, 757	Bauer J 369	Boesen AM 349
Allen PK S2: 41, S2: 97	Baum M 173	Bogman MJJT S1: 43
Amadori D 33	Baumann I 217	Bognel C S3: 59
Amato S 769	Bavli JL 591	Bohlen H 300, S1: 97
Ambesi Impiombato F 513	Bayssas M 527	Bohn U 660
Ameglio F 741	Becker D 772	Boiocchi M 167
Amin T 466	Beckruts KTE S3: 1	Boleti E 601
Amoroso D 337	Beer M 159	Bolis P 627
Anbazhagan R 409	Beijnen JH 90, 133, 259, 951	Bollag W S9: 1, S9: 17
Andersen E 349	Belt RJ 286	Bonadonna G 98, 209, 803, 817, 935, S2: 5
Anderson H 852	Ben-Baruch N 709	Bonfante V 817
Anderson L S2: 65, S2: 117	Benson JR 173	Bonilla F 965
Andreeff M 265	Benz CC 329	Bonnefoi H 771
Ang P-T 87	Berchier MC 641	Bonneterre J 423, S6: 33
Angeli A 763	Berger DP 415	Bontenbal M 858
Angelidou M 601	Bernardi D S2: 37	Boos G 766
Annino L 725	Bernasconi C 427, S2: 53, S2: 101	Boot H 90
Aragoncillo P 660	Bernasconi P 427	Botto B 895
Arber DA S1: 39	Bernhard J 65	Bourcier JD 441
Arbuck SG 757, S6: 1, S6: 59	Berruti A 763	Boven E 415, 733
Armand JP 485	Berry J 453	Braakhuis BJM 415
Armitage JO 689, S2: 161	Bertini M 895	Bradley C 635
Astori C 427, S2: 53, S2: 101	Bertola G 661	Brämswig JH S2: 113
Attili A S7: 15	Bertuccelli M 291, 760	Bramwell V 766
Au E 87	Besa P S2: 97	Brandmaier R S2: 123
Ayoub A 466	Besenval M 37	Branchög I 809
Ayoub J 283	Besznyák I 83	Bready B 286, 468, 646
	Betticher DC 57	Brechot JM 37
<b>B</b>	Bianco AR 269	Breed WP S1: 89
Baars JW 929	Biasi S 209	Bregní M 935
	Biber B 961	Brittinger G S2: 123

Broggini M 575  
 Bron D S2: 85  
 Brooks TE 317  
 Brown R 75  
 Brugger W 943  
 Brugiatelli M 725  
 Brunetti I 291  
 Bruning PF 153, 617  
 Brunner K 717  
 Bruntsch U 375, 543  
 Brusamolino E 427, S2: 53, S2: 101  
 Bruzzi P 760  
 Budach VGF S3: 37  
 Bugat R S6: 33  
 Bullerdiek J S1: 121  
 Bureau G 641  
 Burkhard O 233  
 Burnett AK 19  
 Buser K 253  
 Buter J 659  
 Butow PN 199  
 Buzzoni R S7: 15  
 Byrne A S2: 47

**C**  
 Cabanillas F 265, 317, 847, S2: 41, S2: 59,  
 S2: 73, S2: 79, S2: 97  
 Cafiero F 163  
 Calabresi F 182, 375, 760, S7: 19, S7: 41  
 Canal B 167  
 Canellos GP S2: 121  
 Canevari A 427, S2: 101  
 Canevari S 698  
 Canzonieri V 909  
 Capnist G 725  
 Cappelaere P 521  
 Caraci P 763  
 Caraglia M 269  
 Carbone A S2: 37, S2: 127  
 Cardarelli N 841  
 Carde P S2: 85, S2: 107  
 Carles J 659  
 Carlini P 513  
 Carmichael J S4: 1  
 Carney DN S2: 47  
 Carpano S 741  
 Carrai M 760  
 Carter R 239, 609  
 Casado A 660, 854  
 Casazza AM 703  
 Cassidy J S4: 25  
 Castelli G 427, S2: 53, S2: 101  
 Castiglione M 65, 717, 785  
 Catalano V 841  
 Catimel G 95, 533, 539, 543, 549  
 Cavaliere R 741  
 Cavalli F 7, 568, 689, 717, 901  
 Ceci G 93

Cedar E 579  
 Cellerino R 841  
 Cercato MC 513  
 Ceribelli A 182, 760  
 Cernigoi C 167  
 Cerny T 57  
 Cervantes A 854  
 Chaganti RSK S1: 55  
 Chambers T S7: 53  
 Chaney MA S6: 33  
 Chang AY S6: 45  
 Charrot P 127  
 Chastang Cl 37  
 Chauvin F 95, 127  
 Chavany C S4: 55  
 Chazard M 127, S6: 33  
 Chepic OF 591  
 Chevalier B 495  
 Childs AM 98  
 Chilvers CED 33  
 Chisesi T 725  
 Christensen BE 349  
 Christiansen I S1: 127  
 Cianci C 291, 760  
 Clavel M 95, 495, 521, 527, 533, 539, 543, 549  
 Clavier J 37  
 Clemens MR 850, S9: 33  
 Clerici M 303  
 Clerico M 521  
 Coates AS 65, 98, 249  
 Cocconi G 8, 93  
 Cocquyt VFJ 821, 863  
 Cognetti F 513, 521  
 Coiffier B 19, 397, 437, 507, 873  
 Coleman D 123  
 Coleman T S7: 27  
 Collins J 717  
 Collinson M S7: 27  
 Colmenarejo A 323  
 Colnaghi MI 698  
 Colombat Ph S2: 147  
 Colombatti M 698  
 Coltrman Jr CA S2: 91  
 Comella G 760  
 Conte PF 291, 760, S7: 41  
 Coombes RC 33, 123, S7: 1  
 Corbally N S2: 47  
 Corbella F S2: 101  
 Cordier JF 37  
 Cordon-Cardo C 835  
 Cormier Y 283  
 Correale P 269  
 Cortés-Funes H 225, 457, 717  
 Corthouts B 653  
 Cotto C 290  
 Cowan KH 709  
 Cox JD S2: 97  
 Cox KM 98

Craft PS 305  
 Crecco M 182  
 Crew J S4: 17  
 Cripps MC 441  
 Cross M S1: 79  
 Crowther D 147, 397, S1: 79, S2: 133  
 Cuevas MA 769  
 Cunningham D 123  
 Cunningham D 123, 239, 609  
 Cunningham J 579  
 Curley SA S3: 75  
 Curtin J S6: 55

**D**  
 d'Amore F 349, 397  
 D'Incalci M 627, 697, 877, 893  
 Dabouis G 641  
 Dahl G S1: 93  
 Dahlberg S S2: 91  
 Dal Bo V 909  
 Dalesio OB 113, 521, 795  
 Dalla-Favera R S1: 55  
 Damasio EE 725  
 Danforth D 709  
 Danova M 627  
 Dargenio F 291  
 Dauplat J S6: 33  
 de Bock R S2: 85  
 de Boer-Dennert M 373  
 de Bruijn KM 821  
 de Jong J 901  
 de la Gándara I 323  
 de Mulder PHM 521, 543, 957, S3: 81  
 de Pree C 861  
 de Vries EGE 75, 659  
 de Wit R 656  
 de Witte T 401, S1: 43  
 de Wynter EA 217  
 De Graeff A 957  
 De Laurenzi A S2: 155  
 De Lisi V 93  
 De Marco S 760  
 De Matteis A 337  
 De Oliveira C 854  
 De Pablo JL 854  
 De Wolf-Peeters C S1: 35, S2: 85  
 Deakin D 147  
 Degardin M 423  
 Del Mastro L 163  
 Del Vecchio MR 513  
 Delasalle K 757  
 Delecluse H-J S1: 113  
 Delgado FM 854  
 Delmer A S2: 85  
 Delozier T S7: 19  
 Demaille A 423  
 Denicoff AM 709  
 Depierre A 37

Dervan PA S2: 47  
 Devizzi L 817  
 Dexter TM 217, S1: 79  
 Dhabhar BN 379  
 di Celle PF 725  
 Di Blasio B 93  
 Di Lauro L 741  
 Di Nicola M 935  
 Diaz-Puente MT 225  
 Diaz-Rubio E 660, 854  
 Diehl V 300, S1: 93, S1: 97, S1: 105, S1: 121  
 Dieras V S6: 33  
 Dierlamm J 233  
 Dimopoulos MA 288, 757  
 Dirix LY 653  
 Dittrich C 473  
 Dixon AK 915  
 Djavanmard MP 863  
 Dobbs NA 98  
 Doglioni C 167  
 Dogliotti L 763  
 Dollbaum C 329  
 Dombernowsky P 623, 852  
 Domenech-Santatasana M 659  
 Donehower RC S6: 7  
 Dorr FA 709  
 Douglass Jr HO S3: 49  
 Dowsett M S7: 3  
 Drach J 265  
 Drings P 49  
 Drivsholm L 623  
 Dubbelman AC 113, 133, 179  
 Dubbelman R 90, 343  
 Dubovsky DW 286  
 Ducreux M S3: 59  
 Duez N S2: 85  
 Dufour P S6: 33  
 Dumon JC 359  
 Dumontet C 437  
 Dumortier A 549  
 Dunlop DJ 649  
 Dunlop R 13  
 Dunn SM 199  
 Dupouy N S2: 107  
 Duroux I S4: 55  
 Dux A S1: 121  
 Dyer MJS 409

**E**  
 Ebbs S 409  
 Eckhardt S 83  
 Edelman L S1: 113  
 Edgerton SM 329  
 Eeltink CM 951  
 Eerenberg-Belmer AJM 929  
 Eghbali H S2: 107  
 Ehrlich HJ S2: 123  
 Einzig AI S6: 29

Eisenhauer EA 185, 283, 766  
 Elia M 915  
 Elias D S3: 59  
 Ellis TM 447  
 Emmerich B S1: 79  
 Enblad G 809  
 Eng Tan P 329  
 Engelhard M S2: 123  
 Engelhardt R 943  
 Engert A S1: 97, S1: 121, S2: 123  
 Eppelbaum R 471  
 Erba E 627  
 Erdkamp FL S1: 89  
 Ernst S 185  
 Errante D S2: 37  
 Eschenbach I 49  
 Espania P 965  
 Espinosa E 323  
 Espinouse D 437  
 Ettinger DS S6: 45  
 Evans C 239  
 Evans DB S3: 75  
 Evans WK 441  
 Ezzat AA 453, 466

**F**  
 Fölling Elgjo R 433  
 Fadda M 466  
 Falcone A 291, 760  
 Farber L S2: 123  
 Fazeny B 473  
 Federico M 725  
 Feliu J 323  
 Ferrari L S7: 15  
 Ferreira Filho AF 772  
 Ferrero JM S6: 33  
 Feuilhade F S7: 19  
 Fey MF 57  
 Piebig HH 415  
 Fiegl M 473  
 Finardi C 93  
 Findlay M 239, 609  
 Finet J-F S1: 113  
 Fink U S3: 1, S3: 17, S3: 27, S3: 105  
 Finlay IG 13  
 Finnegan MCM S1: 85  
 Fisher C 753  
 Fisher RI 447, S2: 91  
 Fisher SG 447  
 Fleury J S6: 33  
 Flock M 466  
 Foà R 725, 789  
 Fodstad Ø 415  
 Fonatsch C S1: 121  
 Forastiere AA S6: 51  
 Forbes J 717  
 Ford H 239, 609  
 Ford JM S7: 27, S7: 41

Ford R 265  
 Forni G 789  
 Foss Abrahamsen A 433  
 Fossá SD 245  
 Fountzilas G 33, 159, 601  
 Frame JN 709  
 Franchi M 627  
 Franchin G 553  
 Franchini P S2: 101  
 Francini G 337  
 Francis P S6: 55  
 Franklin HR 113, 375, 471, 527, 533, 543  
 Frasca AM 741  
 Frassoldati A 725  
 Freedman A S2: 143  
 Freilone R 895  
 Freue M S7: 19  
 Frustaci S 167  
 Fuchs R S2: 123  
 Fueger RH 646  
 Fumoleau P S6: 33

**G**  
 Gahrtson G S2: 67  
 Gaidano G S1: 55  
 Gale RP 689  
 Galletto A 861  
 Galligioni E 337  
 Gallo Stampino C 760  
 Gandhi V S2: 79  
 Gandola L 935  
 Gansbacher B 313  
 Garaci E 741  
 García-Conde J 854  
 García Girón C 323  
 García-Prats MD 225  
 Garido P 323  
 Garrone O 163  
 Gause A S1: 93  
 Gavarotti P 895  
 Gaynor ER S2: 91  
 Geiseler B S2: 123  
 Gelber RD 65, 409, 717  
 Genua G 269  
 George N 597  
 Gerhardt D S2: 123  
 Gerhardt H S2: 123  
 Gérinière L 437  
 Gervasio H 854  
 Gescher A 205  
 Ghosh B 709  
 Giannarelli D 513  
 Giannessi PG S7: 41  
 Gianni AM 781, 935  
 Gianni L 98  
 Giannone L 646  
 Giordano M 627  
 Giostra E 861

Gioti A 159  
 Girón GC 854  
 Giwercman A 355  
 Glazer G 123  
 Glick JH S2: 91  
 Glimelius B 189, 809, S1: 127, S2: 67  
 Gloudemans T 277  
 Glover D S7: 31  
 Gnant MFX 863  
 Goday A 659  
 Goedhals L 579  
 Goel R 441  
 Goepel JR S1: 47, S1: 85  
 Goey SH 373  
 Goldhirsch A 65, 409, 717, 785  
 Goldspiel B 709  
 Goldstone AH S2: 147, S2: 151, S2, 155  
 Golomb HM 676  
 Golubeva OM 591  
 Gonzalez JL 660  
 González Barón M 323  
 Goodacre AM 317  
 Goodship AE S7: 53  
 Gorin NC S2: 147  
 Gorostiaga J 854  
 Gospodarowicz M 397  
 Goss G 283  
 Goss P S7: 19  
 Gossmann HH 49  
 Gottstein C S1: 97, S1: 121  
 Goujal P 127  
 Goverde GJ S1: 43  
 Goyns MH S1: 47, S1: 51, S1: 85  
 Grabelsky S S7: 31  
 Gratwohl A 57  
 Green JR S7: 53  
 Greenall MJ S4: 39  
 Gregg R 283  
 Gregoire V S2: 79  
 Grierson AJ S1: 47  
 Grimaldi A 463  
 Grisold W 473  
 Grogan L S2: 47  
 Grogan TM S2: 91  
 Gropp C 49  
 Groshen S 827  
 Grynpas MD S7: 49  
 Guarini A 789  
 Guastalla JP 95, 127, 549, S6: 33  
 Guenzi M 163  
 Gupta RK S1: 117  
 Gustavsson A 809  
 Gustavsson B 961  
 Gusterson B 409, S4: 17  
 Gwyther SJ S4: 3

Hack CE 929  
 Hacking A 717  
 Hafström L 961  
 Hagberg H S1: 75, S1: 127, S2: 67  
 Hagemeister FB 847, S2: 41, S2: 59, S2: 73, S2: 97  
 Hager B 433  
 Haglund U 189  
 Hakes T S6: 55  
 Hamilton-Dutoit SJ S1: 113  
 Hammond DW S1: 47, S1: 51  
 Hanauske AR 533, S2: 123  
 Hancock BW S1: 47, S1: 51, S1: 85, S2: 117  
 Hansen HH 623  
 Hansen M 623  
 Hansen SW 355  
 Haregewoin A 371  
 Harris AL 305, 388  
 Harris M 147  
 Harstrick A 850  
 Hart IR S4: 59  
 Hart MHL 929  
 Hartlapp H-J S2: 123  
 Harvey H S7: 31  
 Havemann K 49, 365  
 Heckel A 733  
 Hecquet B 423  
 Heimans JJ 951  
 Hekman A 179  
 Hélène C S4: 55  
 Hellström KE 703  
 Henane S 290  
 Henderson IC 196  
 Hendriks HR 415  
 Henry-Amar M S2: 107  
 Herman D 37  
 Hermon-Taylor J 123  
 Heron JF 127, 579, S6: 33  
 Hess M S2: 59  
 Hess U 57  
 Hickish T 609  
 Hilgenfeld U 233  
 Hill A 239, 609  
 Hill D 265  
 Hilton AM 179  
 Hirsch F 623  
 Hoefnagel CA 617  
 Hoekman K 277  
 Hoekstra OS 277  
 Höffken K S7: 7  
 Hoffman K 189  
 Hoffmann W 377, S9: 3, S9: 7, S9: 33  
 Hofmann C 901  
 Holle R 49  
 Hollema H 75  
 Holmberg SB 961  
 Holmes FA S6: 23  
 Holtkamp MJ 795

Hong WK 391, S9: 23  
 Horenblas S 179  
 Horner D 423  
 Hörmig-Franz I S2: 113  
 Horning SJ S2: 23  
 Horwitz SB S6: 3  
 Hoskins W S6: 55  
 Hossfeld DK 233, 850  
 Howell A 217, 597  
 Huan SD 441, 644  
 Huber H 473  
 Huber M 757  
 Huhn D S2: 123  
 Hummel M S1: 121  
 Hupperets PS 957  
 Hürny C 65  
 Husband J 239

**I**

Illiger HJ 233  
 Invernizzi R 725  
 Isaacson P 397  
 Ivanova OA 591

**J**

Jacobsen A-B 245  
 Jacoulet P 37  
 Jadayel D 409  
 Jaffe ES S1: 7  
 Jäger W 25  
 Jähne J S3: 33  
 Jakesz R 863  
 Jakobsson M 809  
 James RD 147  
 Jansen WJM 733  
 Järnmark M S2: 67  
 Jayatilake H 409  
 Jebb SA 915  
 Jeekel J S3: 73  
 Jeffers S 474, 827  
 Jendiroba D 265  
 Jensen MK 349  
 Jenzer H 57  
 Joab I S1: 113  
 Johansen P 349  
 Johansson B S2: 67  
 Johansson H S2: 67  
 Johnsen C 717  
 Johnson DH S6: 45  
 Jolivet J 185  
 Jonat W S7: 7  
 Jones AL 123  
 Jones W S6: 55  
 Jones QJ 199  
 Joosten F 957  
 Jordaan JP 579  
 Joss RA 253, 921  
 Judson I 543

**H**  
 Haarstad H 245

Juliussen G S2: 67  
 Jung FA 772  
 Jung W S1: 93  
 Juvekar RR 29

**K**  
 Kadin ME S1: 25  
 Kagevi I 466  
 Kaiser U 365  
 Källner M 809  
 Kantarjian H 288  
 Kanz L 943  
 Kapp U S1: 121  
 Kasra M S7: 49  
 Katz R 265  
 Kaye SB 75, 375, 527, 533, 543, 649, 964  
 Keating MJ 288, S2: 79  
 Keegan P 709  
 Kefer C 447  
 Keith WN 75  
 Kerbrat P 127, 539, S6: 33  
 Kerger J 539  
 Kerr DJ S4: 67  
 Keuning JJ S2: 85  
 Khalifa F 453  
 Khan B 453  
 Khetan R S2: 41  
 Khoury M 49  
 Killander A S2: 67  
 Kimby E S2: 67  
 Kingma BJ 473  
 Kingma DW S1: 7  
 Kirchner V 253  
 Kirkham J 123  
 Kirkpatrick A 521  
 Kitada S S1: 61  
 Klaassen U 233  
 Klastersky J 641  
 Klouvas G 601  
 Knowles DM S1: 55  
 Knowling M 766  
 Köhne-Wömpner C-H S3: 97  
 Kok TC 858  
 Koliren L S7: 41  
 Köppler H 49  
 Kosmidis P 159, 601  
 Kragh Larsen A 679  
 Kreuser ED 233  
 Kriebel R 233  
 Kristensen J S1: 127  
 Krogh-Jensen M 349  
 Kuhn H 49  
 Kuiper CM 733  
 Kvaløy S 433

**L**  
 La Vecchia C 747  
 Lacava J 769

Lamparelli T 725  
 Landoni F 627  
 Langdon SP 415  
 Lange C 217  
 Langhi M 769  
 Larsson R S1: 127  
 Lasser Ph S3: 59  
 Lassere Y 468  
 Lassus M 901  
 Latreille J S7: 41  
 Lauria F 725  
 Lazzarini R S2: 127  
 Lazzarino M 427, S2: 53, S2: 101  
 Le Bail N 533, 539  
 Leardi A 269  
 Lebeau B 37  
 Lee KA S1: 85  
 Lee MS S2: 73  
 Lemarie E 37  
 Lemoine NR S4: 31  
 Lenner P 809  
 Lenner K 49, S2: 123  
 Leone B 769  
 Lepera P S7: 15  
 Lerner R S2: 67  
 Levi F 747  
 Levin B 468, 646  
 Levine AM S2: 29  
 Levis A 895  
 Lewis Jr JL S6: 55  
 Leyva A 772  
 Leyvraz S 369  
 Lhommé C 127, S6: 33  
 Lianes P 225, 457  
 Liber P 641  
 Liberti G S2: 151  
 Lien HH 433  
 Lim J S2: 143  
 Lin YG 646  
 Linch DC S2: 65, S2: 117  
 Lincke C 733  
 Lindemalm C S2: 67  
 Linderholm B S1: 75  
 Lindh J S1: 75  
 Lindnér P 961  
 Lindström A S1: 75  
 Lindtner J 717  
 Lippman SM 391  
 Lipton A S7: 25, S7: 31  
 Lista F S1: 55  
 Lister TA 147, 397, S1: 117, S2: 143  
 Livraghi A S2: 53, S2: 101  
 Lluch A 854  
 Lo Coco F S1: 55  
 Lo Re G 909  
 Löfvenberg E S2: 67  
 Logmans A 656  
 Lohri A 57

Lombardi F 935  
 Lopez M 741  
 López-Brea M 225  
 López Martín E 225  
 Lorusso V 760  
 Lotan R S9: 23  
 Lottici R 93  
 Louie DC S1: 55  
 Luckett R 757  
 Ludwig C 921  
 Ludwig W-D S2: 123  
 Luft T 217  
 Lund B 852  
 Luthor R 847

**M**  
 Maasila P 949  
 Maassen JA 277  
 Macerata R S7: 31  
 Machado VL 772  
 Machiavelli M 769  
 MacLennan KA S2: 117  
 Madsen EL S7: 27  
 Macs RAA 259  
 Magrath IT S1: 67  
 Mahjoubi M S3: 59  
 Mainwaring PN 98  
 Majolino I S2: 151  
 Maldonado A 646  
 Mandard A-M S2: 107  
 Mandjes IA 113, 343  
 Mangioni C 627  
 Mangold C 286  
 Manning Jr JT 317  
 Mans DRA 772  
 Mansi J 609  
 Mantovani A 205  
 Mäntylä M 949  
 Marelli L S1: 113  
 Margison J 597  
 Markman M S6: 55  
 Marrari P 901  
 Marsoni S 303  
 Martin LM 660  
 Martin M 854  
 Martinelli G 921  
 Martinetti A S7: 15  
 Martinez J S7: 19  
 Martínez A 854  
 Marzetti F 513  
 Mattijssen V 533, 957  
 Mattson K 949  
 Mauriac L S7: 19, S7: 41  
 Mayer C S9: 3  
 Mayer F 127  
 Mayordomo JI 225  
 Mazzini G 627

McLaughlin P 847, S2: 41, S2: 59, S2: 73,  
     S2: 79, S2: 97  
 McNally D S7: 53  
 McVie JG 133, 343  
 Medeiros LJ S1: 7  
 Medi F 33  
 Meidahl Petersen P 852  
 Meijer OWM 951  
 Meijerink JPP S1: 43  
 McIef CJM 179  
 Mellink WAM S2: 107  
 Mellstedt H S2: 67  
 Mendiola C 225  
 Mensink EJBM S1: 43  
 Mermilliod B 771  
 Merola MC S2: 127  
 Merrouche Y 549  
 Mertelsmann R 943  
 Mertens WC 185  
 Meusers P S2: 123  
 Meyer H-J S3: 33, S3: 69  
 Meyskens Jr FL S9: 29  
 Michel G 369  
 Michel J 821  
 Michel RTh S7: 19  
 Mickle K 409  
 Mihich E 119  
 Milella M 513  
 Miller L 709  
 Miller TP S2: 91  
 Milleron B 37  
 Minasian LM 313  
 Mirimanoff RO 771  
 Miyashita T S1: 61  
 Mize EM S2: 91  
 Moiseyenko VM 591  
 Mokbel K 173  
 Moliterni A 209, 803  
 Molls M S3: 105  
 Mommens P 641  
 Monconduit M S2: 107  
 Monfardini S 964, S2: 37, S2: 127  
 Monserrat B S6: 7  
 Moore DF 646  
 Moore II DH 329  
 Moore Jr DF 286  
 Moore M 185  
 Morgenstern GR 217  
 Moro D 37  
 Morra E 427, S2: 53, S2: 101  
 Morris M 827  
 Mouridsen H 539  
 Moyano A 323  
 Mrose H 709  
 Mücke S S1: 121  
 Muderspach L 827  
 Muggia FM 474, 662, 827  
 Muldal A 185, 283

Mulder NH 659  
 Müller P S2: 123  
 Müller W 954  
 Murphy SB S1: 31  
 Murray R S7: 11  
 Muttini MP 291  
 Mylonakis N 159, 601

**N**  
 Nadler L S2: 143  
 Namer M 127, S6: 33  
 Naredi P 961  
 Nash A 609  
 Nasti G 661  
 Nathan B 409  
 Nau H S9: 39  
 Neidhart JA 43  
 Neidle S S4: 51  
 Neuenschwander H 253  
 Newell DR S4: 9  
 Nicolò G 163  
 Nicolson M 239, 609  
 Nicolson V 609  
 Nielsen AL 375  
 Noberasco C S7: 15  
 Nome O 433  
 Nooijen WJ 795  
 Noone M 709  
 Noordijk EM S2: 107  
 Norman A 239, 609  
 Norton A 397  
 Nygren P S1: 127  
 Nyrén O 189

**O**  
 O'Brien JP 835  
 O'Brien MER 753  
 O'Brien S S2: 79  
 O'Grady P 549  
 O'Hare M 409  
 O'Shaughnessy JA 709  
 Oberling F S6: 33  
 Oehl S 49  
 Offit K S1: 55  
 Oken MM S2: 91  
 Onetto N S6: 33  
 Ordonez NG 317  
 Ordóñez A 323  
 Orlandi E 427, 895, S2: 53, S2: 101  
 Orlandi F 763  
 Orlov AA 591  
 Orsucci L 895  
 Orth B 253  
 Ortiz E 769  
 Osborne CK 43  
 Osborne RJ 108, 915  
 Öst Å S2: 67  
 Osterwalder B 141

Oza AM 343  
 Ozols RF S6: 39

**P**  
 Pacini P 337  
 Paesmans M 641  
 Pagan O 57, 901  
 Paganini G 463  
 Pagnucco G 427, S2: 53, S2: 101  
 Paillot N 37  
 Palamidas Ph 601  
 Pallesen T 623  
 Palmer PA 957  
 Palumbo R 463  
 Pandita R 379  
 Pandolfi A 760  
 Panetta A 773  
 Pannuti F 773, S7: 19  
 Panousaki E 601  
 Papadakis E 159, 601  
 Parastatidis S 159  
 Parker M 123  
 Parmiani G 789  
 Parwaresch MR 49, S2: 123  
 Pasman PC S1: 89  
 Passalacqua R 93  
 Pate O S2: 73  
 Patt Y 468  
 Pavlidis N 375, 601  
 Paz-Ares L 225, 457  
 Pazdur R 286, 468, 646  
 Pearce R S2: 151, S2: 155  
 Peccatori F 935  
 Peck R S9: 17  
 Pedersen M 349  
 Pedrinis E 954  
 Pees H-W S2: 123  
 Pepe S 269  
 Perez J 769  
 Pérez Carrión R S7: 19  
 Perin T 167  
 Perrault DJ 441  
 Perren T 753  
 Perrin L 861  
 Perrotta A 337  
 Peschel Ch S2: 123  
 Petersen PM 355  
 Peterson HF 65  
 Petrioli R 337  
 Petrylak DP 835  
 Pettengell R S1: 79, S2: 133  
 Pettersson U S2: 67  
 Pezous N 854  
 Pfab R 49  
 Pfahl M S9: 11  
 Pfanner E 291, 760  
 Pfitzner J 233  
 Pflüger K-H 49, 365

Pfreundschuh M S1: 93  
 Philip T 19  
 Phillips M S6: 55  
 Piccart M 375, 527, 533, 543  
 Pichlmayr R S3: 33  
 Pielmeier A S1: 79  
 Pierce LJ 709  
 Piga A 841  
 Pignatti F 741  
 Pinedo HM 277, 733, 929  
 Pinheiro CM 772  
 Pini M 895  
 Pinnarò P 513  
 Pinto A 269  
 Pinto Ferreira E 33  
 Pion J-M 423  
 Pitt P S7: 11  
 Pittaluga S S1: 35  
 Pivano G 763  
 Pizzuti M 895  
 Planting ASTh 373, 858  
 Plunkett W S2: 79  
 Podoloff DA S2: 59  
 Pollera CF 182  
 Possinger K S7: 7  
 Pötter R S2: 113  
 Pouillart P S6: 33  
 Poulakis N 159  
 Pratesi G 415  
 Preti A S2: 97  
 Price K 409  
 Proctor SJ S2: 155  
 Pronzato P 463  
 Prosser IA 441  
 Provata A 601  
 Prové AM 527, 653  
 Provencio M 965  
 Pruvot I S6: 33  
 Pugh WC 317, 847  
 Pugin P 57  
 Puligheddu B 763  
 Punt CJA 473, S3: 87  
 Purugganan R S2: 59

**Q**  
 Quirt I 766  
 Quoix E 37, 290

**R**  
 Rabinovich M 769  
 Radford JA 147  
 Radtke H S2: 123  
 Raemaekers JMM S1: 43  
 Raffeld M S1: 7  
 Raja MA 453  
 Randimbison L 747  
 Rankin EM 179  
 Ranson M 217, 597

Raphael M S1: 113  
 Rasi G 741  
 Rauschecker H 33  
 Ravagnani F 935  
 Ravdin PM 43  
 Rea D S1: 113  
 Rebattu P 95, 549  
 Reed JC S1: 61  
 Reed R 409  
 Reichman B S6: 55  
 Resegotti L 725, 895  
 Reuter V 835  
 Riccardi A 627  
 Ricci S 291, 760  
 Rich TA S3: 9, S3: 75  
 Richard I 127  
 Richel DJ 795  
 Ries F 641  
 Risberg T 245  
 Ritt JL 772  
 Rivera F 225  
 Robért K-H S2: 67  
 Robertson LE S2: 79  
 Rodemann HP 377, S9: 3, S9: 7  
 Rodenhuis S 795  
 Roder JD S3: 1, S3: 17  
 Rodrigues de Oliveira J 772  
 Rodriguez A S2: 97  
 Rodriguez J 317, 847  
 Rodriguez MA 847, S2: 41, S2: 59, S2: 73  
 Rodriguez R 769  
 Rogers GT 879  
 Rohatiner AZS 147, 397, S2: 143  
 Roila F 585  
 Romaguera JE 317, 847, S2: 41, S2: 59,  
 S2: 73  
 Roman L 827  
 Romero A 769  
 Romero Acuña J 769  
 Romero Acuña L 769  
 Roos G S1: 75  
 Rørth M 355  
 Rosenberg SA S2: 17  
 Rosin RD 123  
 Rosing H 259  
 Rossi C 661  
 Rosselli M 741  
 Rosso R 163, 463  
 Rota Scalabrini D 895  
 Rougier Ph S3: 59  
 Rowinsky EK S6: 7, S6: 55  
 Royce CM S7: 19  
 Royds J S1: 85  
 Rubagotti A 337  
 Rubin S S6: 55  
 Rudenstam CM 65, 717  
 Ruiter DJ 957  
 Russell C 827

Ryberg M 852  
**S**  
 Sabatini C 769  
 Sabourian MH 265  
 Sacchini V S7: 15  
 Sacks N 609  
 Saison-Behmoaras E S4: 55  
 Salas C 965  
 Salem P 397  
 Salles G 437  
 Salo J 949  
 Salvadori M 769  
 Salvi F 895  
 Samantas E 159, 601  
 Samuels BL S1: 1, S1: 5, S2: 1  
 Santagostino A S2: 53  
 Santoro A 817  
 Santos R S7: 19  
 Sarcina R 760  
 Sarris AH 265, S2: 73  
 Sassi M 337  
 Sauerbrei W 25  
 Sauter C 921  
 Sauven P 123  
 Scaletzky A 772  
 Schadeck-Gressel C S2: 123  
 Schalhorn A 233  
 Schatzmann E 921  
 Schell-Frederick E S1: 121  
 Schellens JHM 259, 373  
 Schellong G S2: 113  
 Scher HI 835  
 Schiebe M S9: 33  
 Schiller U S9: 3, S9: 7  
 Schimke J 141  
 Schimke RT 119  
 Schjølseth SA 245  
 Schlak I S9: 7  
 Schlimok G S2: 123  
 Schmerber J 641  
 Schmidberger H 377  
 Schmoll H-J S3: 97, S3: 115  
 Schöffski P S3: 97  
 Schornagel JH 521, 795  
 Schouten HC S1: 89, S2: 147  
 Schrijvers D 653  
 Schubotz R 49  
 Schwab G S4: 55  
 Schwartsmann G 772  
 Schwarze EW S2: 113  
 Sculier JP 641  
 Seaman J S7: 31  
 Secondo V 895  
 Seeber S 850  
 Segelov E 249  
 Seidman AD S6: 17  
 Selby P 635

Seleznev IK 591  
 Semiglazov VF 591  
 Senn H-J 65, 141, 409, 717, 921  
 Sergysels R 641  
 Serraino D S2: 37  
 Sessa C 471, 543, 901  
 Shapiro CL 196  
 Sharma SK 879  
 Sheridan E S1: 85  
 Shipley J S4: 17  
 Shipp M 397  
 Sieck J 466  
 Siegenthaler P 921  
 Siegert W S2: 123  
 Siegmund R 233  
 Siena S 935  
 Siewert JR S3: 1, S3: 17, S3: 27  
 Silingardi V 725  
 Simonelli C 661  
 Simonetti GPC 113  
 Simonsson B S2: 67  
 Simpson J 717  
 Sismondi P 337  
 Sjödén P-O 189  
 Skakkebæk NE 355  
 Skarlos DV 159, 601  
 Slaper-Cortenbach ICM 795  
 Sleijfer DTh 659  
 Smetsers TFCM S1: 43  
 Smyth JF 471, 569  
 Snow GB 521  
 Soopenberg O 343  
 Soh LT 468  
 Solal-Celigny P 37  
 Soler-Michel P S6: 33  
 Soltys KM 441  
 Somers R 397, S2: 85, S2: 107  
 Soo E 468  
 Sorio R 964, S2: 37  
 Sosman JA 447  
 Spann W S2: 123  
 Spataro V 954  
 Sphakianoudis G 601  
 Spina M 661  
 Splinter TAW 858  
 Springer CJ 879  
 Stahel R 369  
 Stahl M 850, S3: 27  
 Stalfelt A-M S2: 67  
 Stamatakis L 821  
 Stansfeld AG 147  
 Steger GG 863  
 Stein HJ 507, S3: 17  
 Stein R 123  
 Steinhauer UE 49  
 Steinke B 233  
 Steup WH S3: 91  
 Steward W 527

Stewart DJ 283, 441, 644  
 Stoter G 373, 656  
 Straka C S1: 79  
 Strickler JG S1: 39  
 Strolin Benedetti M 901  
 Stupp R S1: 1, S1: 5, S2: 97  
 Subert R 233  
 Sugarman S 468  
 Sulkes A 471  
 Sunderland MC 43  
 Sundström C S1: 75, S1: 127, S2: 67  
 Surbone A 378  
 Svedmyr E S2: 67  
 Swan F 847, S2: 73, S2: 97  
 Swan Jr F 265, S2: 41, S2: 59  
 Sweetenham JW S2: 155  
 Swerdlow SH S1: 71  
 Swindell R 147  
 Symann ML 19

**T**  
 Taal BG 90, 113  
 Taghipour G S2: 147, S2: 151, S2: 155  
 Tagliaferri P 269  
 Tagnon A 641  
 Takayama S S1: 61  
 Talamini R S2: 127  
 Tammilehto L 949  
 Tan S 753  
 Tanneberger S 773  
 Taphoorn MJB 951  
 Tarasoff P 283  
 Tarella C 935  
 Tattersall MHN 199, 674, 717  
 Te V-C 747  
 Teller FGM 90  
 ten Bokkel Huinink WW 90, 113, 133, 343,  
 375, 471, 527, 617  
 ten Hoeve RFA 617  
 Tenti P 627  
 Terenziani M 803  
 Terhardt E S2: 123  
 Testa NG 217, S1: 79  
 Thatcher N 852  
 Theocharis D 159, 601  
 Thiel E S2: 123  
 Thiriaux J 641  
 Thomas F 290  
 Thomas J S2: 85, S2: 107  
 Thomson Y 597  
 Thor AD 329  
 Thorling K 349  
 Thürliemann B 253, S7: 45  
 Tiebosch A S1: 89  
 Tiemann M 365, S2: 123  
 Tirelli U 553, 661, S2: 37, S2: 85, S2: 107,  
 S2: 127  
 Tobler A 57

Todeschini G 895  
 Toffoli G 167  
 Toma S 463  
 Tomiak AT 441  
 Topuzov EE 591  
 Tomos CS 317  
 Torri V 627  
 Trail PA 703  
 Trillet-Lenoir 290  
 Trott P 123  
 Trovò M 909, S2: 37  
 Truini M 725  
 Trümper L S1: 93  
 Tubiana N S6: 33  
 Tuchais E 37  
 Tueni EA 521  
 Tursz T 527, 539  
 Twelves CJ 98  
 Twentyman PR 394  
 Twycross RG 111  
 Tyrrell CJ S7: 27, S7: 37

**U**  
 Ubezio P 627  
 Udén A-M S2: 67  
 Ulrich W S9: 3  
 Ultmann JE S1: 1, S1: 5, S2: 1  
 Uziely B 474, 827

**V**  
 Vaccher E S2: 37  
 Valagussa P 209, 803, 817  
 Valdés Olmos RA 617  
 Vallejo C 769  
 Van Belle SJ-P 821, 863, S7: 19  
 Van Cutsem O 641  
 Van den Broek P 957  
 van der Burg MEL 373, 656  
 van der Gaast A 656, 858  
 van der Graaf WTA 659  
 van der Schoot CE 795  
 van der Wall E 795  
 van der Water L 597  
 van der Zee AGJ 75  
 van Doorn J 277  
 van Glabbeke M 539, S2: 85  
 Van Hoef MEHM 217  
 van Hoesel QGCM 539  
 van Marck E 653  
 van Meerbeeck J 653  
 van Oosterom AT 539, 653  
 van Pottelsberghe C 539  
 van Tinteren H 617  
 van Tulder MW 153  
 van Vlies B 617  
 van Warmerdam LJC 133, 259  
 Vangsted A 623  
 Vanhoef U 850

Vannozzi G 33  
 Vasey PA 649  
 Vassilopoulos P 33  
 Vaughan Hudson B S2: 65, S2: 117  
 Vaughan Hudson G S2: 65, S2: 117  
 Vennin P S6: 33  
 Venturini M 163  
 Venzon DJ 709  
 Verdonck LF S2: 147  
 Vermeire P 653  
 Vermorken JB 277, 471, 521, 543, 951  
 Veronesi A 909  
 Verweij J 259, 373, 375, 471, 495, 521, 527,  
     533, 539, 543, 656  
 Vici P 741  
 Viero P 895  
 Vile RG S4: 59  
 Villadiego K 659  
 Vincenti M 463  
 Vitelli G 741  
 Vitolo U 895  
 Viviani S 817  
 Vlasveld LT 179  
 Volta C 895  
 Von Hoff DD 487  
 von Rohr A 57  
 Vrints LW S1: 89

**W**  
 Wade III JL 286  
 Wadman B S2: 67  
 Wagener DJTh S3: 81, S3: 87  
 Wagstaff J 277, 929  
 Wahlin A S2: 67  
 Waladkhani AR S9: 33  
 Waldmann TA 689, S1: 13  
 Walker PC S7: 53  
 Wanders J 375, 471, 527, 533, 543  
 Wannenmacher M S2: 113

Weber DM 288, 757  
 Weber W 233  
 Weh HJ 233, 850  
 Wehrle E S7: 19  
 Weisenburger DD S1: 19  
 Weiss B 377  
 Weiss LM S1: 39  
 Whelan JS 147  
 Wierzbicki R 466  
 Wigbout G 113  
 Wilder-Smith CH 141  
 Wildiers J 521  
 Wilke HJ 233, 850, S3: 17, S3: 27, S3: 69,  
     S3: 87  
 Wilkinson PM 147  
 Willemse PHB 659  
 Williams ME S1: 71  
 Wilmanns W S2: 123  
 Wils JA 33, S3: 69, S3: 81  
 Wiltshaw E 753  
 Winderen M 433  
 Winkler U S1: 97  
 Winn RJ 286, 646  
 Wolbers JG 951  
 Wolbink G-J 929  
 Wolf J 300, S1: 105, S1: 121  
 Wolff I 471  
 Woll PJ 597  
 Wong D 283  
 Woods E 33  
 Wouters W S9: 45  
 Wright M S6: 7

**X**  
 Xu X-C S9: 23

**Y**  
 Yang L S2: 79  
 Yau JC 441

Yazigi A 466  
 Ye BH S1: 55  
 Younes A 265, S2: 73  
 Yvers A 217

**Z**  
 Zachariadis E 159  
 Zagonei V 269, S2: 37, S2: 127  
 Zambetti M 209, 803  
 Zamora P 323  
 Zancanaro C 909  
 Zarate-Osorno A S1: 7  
 Zava DT 329  
 Zelenakas K S7: 31  
 Zeller W 49  
 Zifko U 473  
 Zilembo N S7: 15  
 Zola P 337  
 Zoller A 233  
 Zou C-P S9: 23  
 Zucali R 209  
 Zucca E 507  
 Zulian GB 57, 771, 861, 964  
 Zurlo MG 901